Biotech Industry Financials, Performance and Ratios
-
Industry Score
36.8 /100
Rank 75 out of 131 Industries -
Advance/Decline
159/126
-
No. of Companies285
-
Avg. Market Cap2,864
-
Price to Earning Ratio5.21
-
Price to Earning Growth Ratio0.59
-
Price to Book Ratio16.12
-
Return on Equity16.39
-
Return on Capital Employed-
-
Return on Assets5.72
-
Dividend yield 1 year %0.28 %
-
Net Profit Growth Annual YoY %58.27 %
-
Net Profit Growth Qtr YoY %-58.54 %
-
Net Profit Growth Qtr QoQ %-153.85 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,592.2
|
23.2
|
L
 -2.9%
H
23.1
24.0
|
L
 -4.5%
H
23.1
24.5
|
L
 6.8%
H
21.6
26.2
|
L
 -3.2%
H
19.4
26.3
|
L
 72.4%
H
13.2
27.7
|
L
 132.3%
H
8.0
27.7
|
L
 -34.0%
H
7.9
37.5
|
L
H
7.9
37.6
|
| Nuvation Bio Inc (Class A) |
|
2,061.4
|
5.9
|
L
 2.8%
H
5.7
6.1
|
L
 15.2%
H
5.0
6.1
|
L
 25.4%
H
4.5
6.1
|
L
 40.3%
H
4.0
6.1
|
L
 200.5%
H
1.8
9.8
|
L
 238.3%
H
1.0
9.8
|
L
 -38.3%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
3,506.6
|
27.9
|
L
 2.4%
H
26.7
28.3
|
L
 15.3%
H
23.3
28.3
|
L
 19.0%
H
21.8
28.3
|
L
 28.8%
H
20
28.7
|
L
 223.4%
H
7.9
28.7
|
L
 44.7%
H
6.5
28.7
|
L
 22.5%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
215.1
|
4.4
|
L
 -2.5%
H
4.2
4.5
|
L
 6.1%
H
4.0
4.8
|
L
 -3.1%
H
4.0
5.2
|
L
 21.2%
H
3.2
5.5
|
L
 108.1%
H
1.6
5.5
|
L
 -44.5%
H
1.2
8.1
|
L
 -83.9%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,731.5
|
5.7
|
L
 -1.2%
H
5.5
5.9
|
L
 7.8%
H
5.0
5.9
|
L
 9.0%
H
5.0
6.8
|
L
 66.8%
H
3.2
6.8
|
L
 66.3%
H
2.7
6.8
|
L
 -21.3%
H
1.9
8.1
|
L
 -74.3%
H
1.9
22.6
|
L
H
1.9
71.9
|
| Adma Biologics Inc |
|
2,016.4
|
8.7
|
L
 1.5%
H
8.5
8.8
|
L
 2.4%
H
8.3
8.8
|
L
 5.6%
H
7.5
8.9
|
L
 -39.3%
H
7.2
14.8
|
L
 -51.0%
H
7.2
20.5
|
L
 124.2%
H
3.1
25.7
|
L
 427.3%
H
1.0
25.7
|
L
 23.2%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,786.4
|
17.4
|
L
 0.2%
H
17.1
17.9
|
L
 -0.3%
H
15.9
18.1
|
L
 25.4%
H
13.7
19.5
|
L
 28.2%
H
12.0
19.5
|
L
 67.7%
H
10.0
20.8
|
L
 141.1%
H
2.3
20.8
|
L
 -56.1%
H
2.3
43.4
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
0.0
|
0.0
|
L
 100%
H
0.0
0.1
|
L
 300%
H
0
0.1
|
L
 -92.3%
H
0
0.4
|
L
 -99.9%
H
0
35.6
|
L
 -100%
H
0
53453.5
|
L
 -100.0%
H
0
10000000000
|
L
 -100.0%
H
0
10000000000
|
L
H
0
10000000000
|
| Agenus Inc |
|
127.4
|
3.1
|
L
 0.7%
H
3.0
3.2
|
L
 -5.9%
H
2.9
3.4
|
L
 -1.6%
H
2.9
3.5
|
L
 -17.5%
H
2.9
5.1
|
L
 -36.0%
H
2.7
7.3
|
L
 -91.4%
H
1.4
196
|
L
 -97.0%
H
1.4
196
|
L
 -96.2%
H
1.4
196
|
| Aeglea BioTherapeutics Inc |
|
406.2
|
100.3
|
L
 13.6%
H
95
101.7
|
L
 20.0%
H
81.7
101.7
|
L
 35.5%
H
68.5
101.7
|
L
 143.2%
H
40.9
101.7
|
L
 568.4%
H
14
101.7
|
L
 780%
H
8.4
101.7
|
L
 -36.5%
H
2.7
212.5
|
L
 -9.9%
H
2.7
300
|
| Avalon GloboCare Corp |
|
4.3
|
0.4
|
L
H
0.3
0.4
|
L
 5.9%
H
0.3
0.4
|
L
 -5.3%
H
0.3
0.4
|
L
 -36.8%
H
0.2
0.7
|
L
 -86.4%
H
0.2
4.7
|
L
 -79.8%
H
0.2
11.7
|
L
 -96.3%
H
0.2
11.9
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
123.1
|
2.0
|
L
 -0.5%
H
2
2.2
|
L
 15.9%
H
1.7
2.2
|
L
 31.6%
H
1.5
2.2
|
L
 12.7%
H
1.5
2.3
|
L
 -33.1%
H
1.1
6.2
|
L
 -73.7%
H
1.1
8.5
|
L
 -82.0%
H
1.1
12.0
|
L
 -60.6%
H
1.1
16.7
|
| Alector Inc |
|
201.0
|
1.8
|
L
 1.7%
H
1.7
1.9
|
L
 22.3%
H
1.4
1.9
|
L
 -18.1%
H
1.4
2.3
|
L
 -11.7%
H
1.4
2.7
|
L
 23.1%
H
1.1
3.4
|
L
 -75.2%
H
0.9
9.1
|
L
 -91.5%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
714.5
|
2.1
|
L
 -1.4%
H
2.0
2.2
|
L
 6.7%
H
1.9
2.2
|
L
 3.5%
H
1.8
2.3
|
L
H
1.8
4.5
|
L
 68.3%
H
1.0
4.5
|
L
 -56.0%
H
0.9
6.1
|
L
 -91.4%
H
0.9
27.9
|
L
H
0.9
55
|
| Altimmune Inc |
|
571.8
|
2.9
|
L
 0.3%
H
2.9
3.0
|
L
 11.4%
H
2.6
3.0
|
L
 1.4%
H
2.6
3.1
|
L
 -12.0%
H
2.6
3.6
|
L
 -58.2%
H
2.6
7.7
|
L
 -29.3%
H
2.1
14.8
|
L
 -81.1%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
1,248.0
|
3.7
|
L
 1.1%
H
3.7
3.8
|
L
 -13.0%
H
3.6
4.1
|
L
 10.5%
H
2.9
4.6
|
L
 4.5%
H
2.9
4.6
|
L
 -60.5%
H
2.9
9.9
|
L
 -53.6%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
106.1
|
4.5
|
L
 1.4%
H
4.3
4.5
|
L
 4.5%
H
4.3
4.8
|
L
 -9.4%
H
4.0
5.6
|
L
 -32.1%
H
4.0
7.1
|
L
 85.8%
H
2.1
11.9
|
L
 40.7%
H
0.4
12.9
|
L
 -78.2%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Amgen |
|
187,100.7
|
346.7
|
L
 0.6%
H
345.5
349.4
|
L
 -1.1%
H
334.1
353.7
|
L
 2.2%
H
322.3
358.5
|
L
 -0.3%
H
320.5
359.4
|
L
 19.8%
H
267.8
391.3
|
L
 50.9%
H
218.4
391.3
|
L
 44.5%
H
198.6
391.3
|
L
 131.4%
H
133.6
391.3
|
| AnaptysBio Inc |
|
1,714.6
|
58.9
|
L
 -1.8%
H
58.9
62.3
|
L
 -1.0%
H
55.2
62.3
|
L
 -1.3%
H
50.1
62.3
|
L
 -5.5%
H
44
73.3
|
L
 154.3%
H
17.1
73.3
|
L
 194.2%
H
12.2
73.3
|
L
 138.7%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,875.2
|
82.5
|
L
 2.4%
H
80.6
83.0
|
L
 0.2%
H
78.4
83.4
|
L
 -0.3%
H
73.5
84.0
|
L
 10.5%
H
72.6
87.8
|
L
 25.8%
H
62.6
99.5
|
L
 60.0%
H
48.2
99.5
|
L
 148.7%
H
22.3
99.5
|
L
 56.2%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
93.2
|
2.7
|
L
 -1.1%
H
2.7
2.9
|
L
 10.5%
H
2.5
3.0
|
L
 -1.8%
H
2.3
3.0
|
L
 3.4%
H
2.3
3.2
|
L
 -18.9%
H
2.3
5.5
|
L
 -16.0%
H
2.1
5.5
|
L
 -29.6%
H
2.1
6.5
|
L
 -16.0%
H
0.6
8.1
|
| AN2 Therapeutics Inc |
|
189.8
|
5.3
|
L
 -2.4%
H
5.0
5.5
|
L
 7.3%
H
4.1
5.5
|
L
 8.7%
H
3.7
5.5
|
L
 31.8%
H
2.9
5.5
|
L
 379.1%
H
1
6.9
|
L
 -25.2%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
3.1
|
0.4
|
L
H
0.4
0.4
|
L
 -6.5%
H
0.4
0.5
|
L
 13.2%
H
0.4
0.6
|
L
 -46.9%
H
0.4
0.9
|
L
 -91.9%
H
0.4
7.2
|
L
 -100.0%
H
0.4
27900
|
L
 -100.0%
H
0.4
121500
|
L
 -100.0%
H
0.4
2167200
|
| Aptevo Therapeutics Inc |
|
5.9
|
4.7
|
L
 -0.8%
H
4.6
4.8
|
L
 0.2%
H
4.5
4.9
|
L
 -4.9%
H
4.4
5.5
|
L
 3.3%
H
3.8
5.7
|
L
 -93.7%
H
3.8
70.7
|
L
 -100.0%
H
3.8
1078387.2
|
L
 -100.0%
H
3.8
14729714.3
|
L
H
3.8
68020444.8
|
| AquaBounty Tech Inc |
|
5.2
|
1.0
|
L
H
1.0
1.1
|
L
 -2.9%
H
0.9
1.1
|
L
 3.1%
H
0.9
1.1
|
L
 6.3%
H
0.9
1.2
|
L
 26.3%
H
0.7
3.0
|
L
 -86.7%
H
0.5
8.2
|
L
 -99.1%
H
0.5
124.6
|
L
H
0.5
610
|
| Arvinas Inc |
|
520.7
|
8.1
|
L
 4.3%
H
7.6
8.1
|
L
 7.7%
H
7.3
8.1
|
L
 -11.2%
H
7.0
9.2
|
L
 -26.2%
H
7.0
12.1
|
L
 8.5%
H
6.1
14.5
|
L
 -69.9%
H
5.9
53.1
|
L
 -89.1%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
11,236.2
|
79.8
|
L
 -2.7%
H
79.7
82.5
|
L
 3.4%
H
74.8
84.6
|
L
 6.4%
H
69.3
84.6
|
L
 41.6%
H
55.0
84.6
|
L
 420.7%
H
14.3
84.6
|
L
 124.4%
H
9.6
84.6
|
L
 -10.2%
H
9.6
93.7
|
L
 1304.4%
H
1.2
93.7
|
| LeonaBio Inc |
|
78.8
|
8.4
|
L
 1.5%
H
7.9
8.4
|
L
 -0.7%
H
7.8
8.5
|
L
 -18.8%
H
7.8
11.1
|
L
 -15.4%
H
7.8
12.5
|
L
 176.9%
H
2.9
14.2
|
L
 -72.0%
H
2.2
43.0
|
L
 -91.9%
H
2.2
166.5
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
2,291.7
|
17.8
|
L
 1.7%
H
17.1
18.0
|
L
 11.4%
H
15.9
18.4
|
L
 17.1%
H
15.0
18.4
|
L
 27.1%
H
13.8
18.4
|
L
 129.3%
H
7.3
18.4
|
L
 87.2%
H
4.7
18.4
|
L
 27.2%
H
4.1
34.0
|
L
 572.5%
H
1.7
34.0
|
| Aura Biosciences Inc |
|
739.2
|
7.2
|
L
 2.9%
H
6.6
7.3
|
L
 10.9%
H
6.2
7.3
|
L
 -5.9%
H
6.0
7.9
|
L
 9.2%
H
6.0
9.5
|
L
 18.4%
H
4.7
9.5
|
L
 -42.9%
H
4.3
12.8
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
574.9
|
30.5
|
L
 0.4%
H
29.5
31.3
|
L
 3.7%
H
28.3
31.3
|
L
 4.6%
H
27
32.3
|
L
 2.0%
H
26.3
32.3
|
L
 53.8%
H
14.4
36.0
|
L
 162.7%
H
1.4
61.1
|
L
 -72.9%
H
1.4
132
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,306.7
|
21.5
|
L
 10.4%
H
19
21.5
|
L
 33.4%
H
15.2
21.5
|
L
 -3.3%
H
14.3
22.8
|
L
 53.4%
H
12.9
28
|
L
 117.1%
H
6.7
28
|
L
 -96.2%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
239.1
|
2.6
|
L
 1.6%
H
2.5
2.7
|
L
 3.2%
H
2.4
2.8
|
L
 -4.4%
H
2.4
3.1
|
L
 -36.5%
H
2.4
4.6
|
L
 -71.6%
H
2.4
14.0
|
L
 -68.9%
H
2.4
14.4
|
L
 -89.2%
H
2.4
31.5
|
L
 -37.8%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
12,586.0
|
244.6
|
L
 -1.3%
H
244.6
252.0
|
L
 -3.5%
H
244.6
260.2
|
L
 3.7%
H
217.2
260.2
|
L
 55.9%
H
152.3
260.2
|
L
 142.9%
H
96.1
260.2
|
L
 170.7%
H
55.0
260.2
|
L
 243.7%
H
19.4
260.2
|
L
 3419.1%
H
1.9
260.2
|
| Aziyo Biologics Inc (Class A) |
|
-
|
1
|
L
 -5.7%
H
1
1.1
|
L
 3.1%
H
1.0
1.1
|
L
 -13.8%
H
0.9
1.3
|
L
 -9.1%
H
0.9
1.3
|
L
 -44.8%
H
0.5
2.6
|
L
 -61.7%
H
0.5
2.8
|
L
 -90.2%
H
0.5
11.1
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
17.6
|
11.2
|
L
 -0.3%
H
10.7
12.2
|
L
 -15.0%
H
10.6
14.0
|
L
 -38.7%
H
10.6
29.3
|
L
 115.4%
H
3.0
29.3
|
L
 -75%
H
3.0
49.6
|
L
 -91.5%
H
3.0
219.8
|
L
 -99.2%
H
3.0
1504
|
L
 -99.9%
H
3.0
17759.8
|
| Autolus Therapeutics PLC (ADR) |
|
436.5
|
1.6
|
L
 10.1%
H
1.5
1.7
|
L
 9.3%
H
1.5
1.7
|
L
 -3.5%
H
1.4
1.9
|
L
 19.7%
H
1.2
2.0
|
L
 -20%
H
1.2
2.7
|
L
 -38.8%
H
1.1
7.5
|
L
 -76.5%
H
1.1
7.9
|
L
H
1.1
53.2
|
| BridgeBio Pharma Inc |
|
13,442.0
|
68.6
|
L
 -0.4%
H
68.0
69.9
|
L
 0.9%
H
65.6
69.9
|
L
 -0.7%
H
62.5
69.9
|
L
 0.1%
H
62.5
84.8
|
L
 64.5%
H
41.3
84.9
|
L
 325.2%
H
15.4
84.9
|
L
 13.7%
H
5.0
84.9
|
L
H
5.0
84.9
|
| BioAtla Inc |
|
5.9
|
3.6
|
L
 -1.7%
H
3.5
3.8
|
L
 -1.7%
H
3.3
4.2
|
L
 -3.5%
H
3.1
4.2
|
L
 -57.9%
H
3.1
8.9
|
L
 -82.2%
H
3.1
71.5
|
L
 -98.1%
H
3.1
201
|
L
 -99.8%
H
3.1
2393.0
|
L
H
3.1
3831.5
|
| BioCardia Inc |
|
14.9
|
1
|
L
 3.1%
H
0.9
1.0
|
L
 20.5%
H
0.8
1.0
|
L
 4.2%
H
0.8
1.8
|
L
 -16.7%
H
0.8
1.8
|
L
 -51.9%
H
0.8
2.5
|
L
 -97.2%
H
0.8
43.2
|
L
 -98.6%
H
0.8
75.8
|
L
 -99.6%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,399.3
|
9.4
|
L
 3.3%
H
9.1
9.5
|
L
 4.2%
H
8.8
9.5
|
L
 13.9%
H
8.1
9.5
|
L
 -2.7%
H
7.8
10.1
|
L
 -6.5%
H
6
10.3
|
L
 34.9%
H
4.0
11.3
|
L
 -43.3%
H
4.0
20.0
|
L
 235.9%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
26.2
|
3.0
|
L
H
3.0
3.2
|
L
 9.9%
H
2.7
3.2
|
L
 -13.8%
H
2.6
3.7
|
L
 -28.0%
H
2.6
4.7
|
L
 -99.0%
H
2.6
316
|
L
 -100.0%
H
2.6
11275.5
|
L
 -100.0%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
83250
|
| Black Diamond Therapeutics Inc |
|
92.3
|
1.6
|
L
H
1.6
1.7
|
L
 -6.4%
H
1.6
1.8
|
L
 -29.4%
H
1.6
2.5
|
L
 -23.7%
H
1.6
4.0
|
L
 -30.9%
H
1.6
4.9
|
L
 -13.4%
H
1.2
7.7
|
L
 -86.8%
H
1.2
13.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,422.8
|
33.3
|
L
 -6.4%
H
32.8
36.7
|
L
 6.9%
H
30.2
36.9
|
L
 16.2%
H
28.3
36.9
|
L
 35.1%
H
21.6
36.9
|
L
 98.5%
H
15.6
36.9
|
L
 2.3%
H
13.5
49.5
|
L
 -61.3%
H
13.5
138.5
|
L
H
13
138.5
|
| Biogen |
|
29,339.9
|
198.7
|
L
 -0.5%
H
198.4
201.2
|
L
 0.1%
H
193.2
201.8
|
L
 2.6%
H
184.9
203.5
|
L
 9.5%
H
168.6
206.0
|
L
 56.4%
H
121.1
206.0
|
L
 -32.4%
H
110.0
293.5
|
L
 -46.9%
H
110.0
376.0
|
L
 -8.0%
H
110.0
468.6
|
| BioVie Inc |
|
14.7
|
2.0
|
L
 0.5%
H
1.8
2.0
|
L
 17.5%
H
1.6
2.1
|
L
 28.3%
H
1.4
2.1
|
L
 62.5%
H
1.3
2.1
|
L
 -81.1%
H
1.1
10.9
|
L
 -99.7%
H
1.1
629
|
L
 -99.9%
H
1.1
1790.1
|
L
 -99.9%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
10,982.4
|
56.8
|
L
 1.7%
H
55.7
57
|
L
 2.1%
H
54.3
57
|
L
 5.1%
H
52.2
58.3
|
L
 5.0%
H
49.3
58.3
|
L
 3.3%
H
49.3
66.3
|
L
 -40.6%
H
49.3
99.6
|
L
 -30.0%
H
49.3
117.8
|
L
 -30.9%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
13.2
|
1.2
|
L
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -7.3%
H
1.1
1.4
|
L
H
1.1
1.5
|
L
 -64.1%
H
1.1
5.5
|
L
 -81.9%
H
0.1
11.6
|
L
 -98.4%
H
0.1
82
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
443.9
|
12.9
|
L
 5.0%
H
11.7
13.2
|
L
 14.0%
H
10.9
13.2
|
L
 15.1%
H
10
13.2
|
L
 17.7%
H
10.0
14.3
|
L
 -11.6%
H
9.9
16.8
|
L
 250.1%
H
1.9
17.2
|
L
 -82.0%
H
1.9
81.3
|
L
 -96.1%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
9.8
|
1.2
|
L
H
1.2
1.3
|
L
 -5.5%
H
1.2
1.3
|
L
 -4.7%
H
1.2
1.5
|
L
 -15.4%
H
1.1
1.5
|
L
 -19.3%
H
1.1
3.4
|
L
 -99.2%
H
1.1
180
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
39.8
|
1.3
|
L
 -0.8%
H
1.3
1.3
|
L
 11.2%
H
1.1
1.3
|
L
 14.2%
H
1.1
1.4
|
L
 -14.6%
H
1.0
1.5
|
L
 -19.4%
H
1.0
8.1
|
L
 -93.2%
H
0.2
19.1
|
L
 -96.5%
H
0.2
36.5
|
L
H
0.2
71.5
|
| Bicycle Therapeutics PLC (ADR) |
|
279.2
|
4
|
L
 0.5%
H
4.0
4.1
|
L
 -3.6%
H
4.0
4.2
|
L
 -12.1%
H
4.0
4.7
|
L
 -8.1%
H
4.0
5.4
|
L
 -46.1%
H
4.0
9.2
|
L
 -85.1%
H
4.0
28.7
|
L
 -86.5%
H
4.0
62.1
|
L
H
4.0
62.1
|
| BioNTech SE (ADR) |
|
22,969.5
|
90.8
|
L
 0.7%
H
90.1
91.7
|
L
 0.0%
H
89.3
93.3
|
L
 -1.4%
H
85.0
97.4
|
L
 1.8%
H
84.8
113.3
|
L
 -14.7%
H
79.5
124
|
L
 -15.4%
H
76.5
131.5
|
L
 -61.6%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
489.2
|
3
|
L
 -0.3%
H
2.9
3.1
|
L
 -0.3%
H
2.8
3.1
|
L
 -17.8%
H
2.8
4.1
|
L
 2.0%
H
2.5
4.2
|
L
 67.6%
H
1.3
4.2
|
L
 -75.8%
H
1.0
26.4
|
L
 -59.1%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
13.0
|
0.8
|
L
 5.1%
H
0.8
0.8
|
L
 -5.8%
H
0.8
0.9
|
L
 30.2%
H
0.6
1.1
|
L
 41.4%
H
0.5
1.1
|
L
 -50%
H
0.5
7.2
|
L
 -76.9%
H
0.5
8.4
|
L
 -98.8%
H
0.5
98.8
|
L
H
0.5
530.3
|
| Tvardi Therapeutics Inc |
|
23.3
|
2.5
|
L
 -7.5%
H
2.4
2.7
|
L
 -7.1%
H
2.4
2.8
|
L
 -30.5%
H
2.4
3.6
|
L
 -29.6%
H
2.4
4.3
|
L
 -90.4%
H
2.4
43.7
|
L
 -98.1%
H
2.4
160.2
|
L
 -99.5%
H
2.4
681.5
|
L
 -98.6%
H
2.4
1067.3
|
| Crescent Biopharma Inc |
|
-
|
17.9
|
L
 1.9%
H
16.8
18.2
|
L
 -1.5%
H
16.8
18.9
|
L
 -13.7%
H
16.5
22.5
|
L
 64.3%
H
10.3
27.4
|
L
 19.4%
H
8.7
27.4
|
L
 275.5%
H
4.4
27.4
|
L
 73.4%
H
0.9
27.4
|
L
 -66.3%
H
0.9
90.3
|
| C4 Therapeutics Inc |
|
466.6
|
4.2
|
L
 2.4%
H
4.0
4.5
|
L
 10.5%
H
3.6
4.5
|
L
 18.5%
H
3.4
4.6
|
L
 56.3%
H
2.3
4.6
|
L
 197.2%
H
1.4
4.6
|
L
 46.5%
H
1.1
11.9
|
L
 -89.0%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
191.1
|
2.0
|
L
 -2.4%
H
2.0
2.1
|
L
H
2.0
2.1
|
L
 -27.9%
H
2.0
2.8
|
L
 -3.4%
H
2.0
3.2
|
L
 23.2%
H
1.3
3.2
|
L
 92.4%
H
0.5
3.2
|
L
 -73.7%
H
0.5
9.2
|
L
 -70.9%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
143.2
|
1.6
|
L
 -4.8%
H
1.6
1.8
|
L
 32.2%
H
1.2
1.8
|
L
 27.0%
H
1.1
1.8
|
L
 49.5%
H
0.6
1.8
|
L
 515.4%
H
0.3
3.8
|
L
 -39.6%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Co-Diagnostics Inc |
|
12.3
|
3.3
|
L
 6.7%
H
3.0
3.5
|
L
 -11.9%
H
3.0
4.0
|
L
 -34.3%
H
3.0
13.5
|
L
 28.6%
H
1.3
13.5
|
L
 -57.6%
H
1.3
46.5
|
L
 -89.7%
H
1.3
66.9
|
L
 -98.7%
H
1.3
354.6
|
L
H
1.3
929.7
|
| Z Squared Inc |
|
663.5
|
12.9
|
L
 -12.3%
H
12
14.5
|
L
 1.0%
H
12
16.9
|
L
 43.7%
H
8.5
16.9
|
L
 14.2%
H
8
18.8
|
L
 70.6%
H
6.9
21.4
|
L
 -59.7%
H
2.3
34.2
|
L
 30.3%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
6,187.1
|
36.2
|
L
 1.0%
H
34.7
36.9
|
L
 9.2%
H
32.4
36.9
|
L
 10.8%
H
30.9
36.9
|
L
 8.5%
H
30.9
39.4
|
L
 400.8%
H
6.9
43.7
|
L
 202.0%
H
3.7
43.7
|
L
 323.5%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Caribou Biosciences Inc |
|
165.6
|
1.7
|
L
 1.8%
H
1.6
1.7
|
L
 0.6%
H
1.6
1.8
|
L
 -20.5%
H
1.6
2.5
|
L
 -10.7%
H
1.6
2.5
|
L
 24.6%
H
1.2
3.5
|
L
 -60.8%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
121.0
|
1.1
|
L
 -0.9%
H
1.1
1.1
|
L
H
1.0
1.1
|
L
 -20.5%
H
1.0
1.4
|
L
 12.9%
H
0.9
1.7
|
L
 -15.3%
H
0.9
1.7
|
L
 25%
H
0.7
3.1
|
L
 -65.8%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
14.0
|
0.4
|
L
 -16.3%
H
0.4
0.4
|
L
 -14.3%
H
0.4
0.5
|
L
 -28%
H
0.4
0.6
|
L
 -53.3%
H
0.4
0.8
|
L
 -83.3%
H
0.4
2.5
|
L
 -97.7%
H
0.4
18
|
L
 -99.8%
H
0.4
180.8
|
L
 -99.8%
H
0.4
372
|
| CorMedix Inc |
|
678.6
|
8.7
|
L
 -1.9%
H
8.6
9.0
|
L
 0.7%
H
8.5
9.1
|
L
 8.4%
H
8.0
9.1
|
L
 38.4%
H
6.3
9.1
|
L
 -36.4%
H
6.1
17.4
|
L
 52.0%
H
2.6
17.4
|
L
 13.8%
H
2.6
17.4
|
L
 -16.8%
H
0.9
18.8
|
| CRISPR Therapeutics AG |
|
5,301.4
|
53.8
|
L
 -1.0%
H
53.1
56.1
|
L
 2.3%
H
51.3
56.1
|
L
 6.9%
H
49.0
59
|
L
 16.4%
H
44.1
59.4
|
L
 21.7%
H
43.2
78.5
|
L
 -5.5%
H
30.0
91.1
|
L
 -58.3%
H
30.0
169.8
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
86.5
|
6.2
|
L
 -0.3%
H
6.2
6.4
|
L
 -1.7%
H
6.1
7
|
L
 3.7%
H
5.6
7
|
L
 6.3%
H
5.6
7
|
L
 -24.9%
H
5.5
9.6
|
L
 8.9%
H
3.6
12.0
|
L
 -30.9%
H
3.6
12.0
|
L
 180.6%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
115.5
|
27.5
|
L
 -10.5%
H
25.8
30.6
|
L
 6.6%
H
23.2
33.0
|
L
 28.1%
H
19.8
33.0
|
L
 244.6%
H
5.0
41.4
|
L
 30.8%
H
5.0
41.4
|
L
 -76.5%
H
5.0
146.7
|
L
 -92.5%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
9.9
|
3.2
|
L
 0.9%
H
3.1
3.4
|
L
 -3.6%
H
3.0
3.7
|
L
 -38.2%
H
3.0
5.6
|
L
 -50.8%
H
3.0
7.3
|
L
 -74.0%
H
3.0
14.6
|
L
 105.8%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
10.9
|
1.5
|
L
H
1.5
1.6
|
L
 -4.4%
H
1.5
1.8
|
L
 -25.3%
H
1.5
2.1
|
L
 -15.2%
H
1.5
2.1
|
L
 -68.5%
H
1.4
5.0
|
L
 -71.8%
H
1.4
10.2
|
L
 -98.3%
H
1.4
96.2
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
1,709.8
|
12.7
|
L
 0.3%
H
12.2
13
|
L
 7.5%
H
11.2
13.2
|
L
 7.3%
H
10.7
14.8
|
L
 134.2%
H
4.9
14.8
|
L
 173.7%
H
2.3
14.8
|
L
 58.6%
H
2.3
14.8
|
L
 -63.7%
H
2.3
49.5
|
L
H
2.3
61.7
|
| Denali Therapeutics Inc |
|
3,934.4
|
24.8
|
L
 3.1%
H
23.5
25.3
|
L
 11.6%
H
21.7
25.3
|
L
 33.0%
H
18.6
25.3
|
L
 22.9%
H
17.7
25.3
|
L
 78.5%
H
12.6
25.3
|
L
 -19.1%
H
10.6
33.3
|
L
 -64.1%
H
10.6
79.7
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
69.9
|
3.1
|
L
 -2.5%
H
3.1
3.2
|
L
 -5.2%
H
3.1
3.5
|
L
 -4.6%
H
3
3.8
|
L
 8.0%
H
2.7
4.6
|
L
 -45.6%
H
2.7
8.4
|
L
 8.4%
H
0.8
13.6
|
L
 -81.1%
H
0.8
20.6
|
L
 -98.0%
H
0.8
308.4
|
| DarioHealth Corp |
|
43.1
|
5.9
|
L
 -6.9%
H
5.9
6.3
|
L
 -17.5%
H
5.9
7.3
|
L
 -24.9%
H
5.9
8.1
|
L
 -26.2%
H
5.9
9.6
|
L
 -57.3%
H
5.9
17.7
|
L
 -92.1%
H
5.9
85.2
|
L
 -98.5%
H
5.9
476
|
L
 -99.7%
H
5.9
2080
|
| Bright Minds Biosciences Inc |
|
655.3
|
66.8
|
L
 5.2%
H
63.1
68.2
|
L
 12.9%
H
56.5
68.2
|
L
 -20.0%
H
56.5
92
|
L
 -6.7%
H
56.5
92.4
|
L
 144.6%
H
23.2
123.8
|
L
 2047.6%
H
0.9
123.8
|
L
 191.7%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
853.8
|
13.7
|
L
 -0.2%
H
13.4
14.1
|
L
 22.7%
H
10.5
14.1
|
L
 24.6%
H
9.9
14.1
|
L
 32.6%
H
9.9
17.3
|
L
 265.5%
H
3.3
17.3
|
L
 144.5%
H
1.9
17.3
|
L
 -41.2%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
183.2
|
7.1
|
L
 0.3%
H
6.8
7.3
|
L
 14.3%
H
6.1
7.3
|
L
 -1.8%
H
6
8.2
|
L
 8.9%
H
5.4
8.6
|
L
 48.2%
H
3.5
8.8
|
L
 1124.1%
H
0.3
19.4
|
L
 -33.3%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,392.2
|
20.5
|
L
 -1.7%
H
20.4
21.5
|
L
 9.6%
H
17.6
21.5
|
L
 18.1%
H
16.6
21.5
|
L
 16.9%
H
15.9
21.5
|
L
 98.8%
H
8.1
25
|
L
 74.6%
H
6.4
47.5
|
L
 -1.6%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
419.0
|
2.7
|
L
 -2.5%
H
2.7
2.9
|
L
 11.0%
H
2.4
2.9
|
L
 -1.1%
H
2.4
3.9
|
L
 16.7%
H
2.1
3.9
|
L
 23.0%
H
1.7
4.5
|
L
 -66.0%
H
0.9
11.7
|
L
 -92.5%
H
0.9
73.0
|
L
 -90.3%
H
0.9
100.0
|
| Eloxx Pharma |
|
43.0
|
12.5
|
L
 -9.9%
H
11.3
13.0
|
L
 -14.9%
H
11.3
15.9
|
L
 207.4%
H
8.2
17.5
|
L
 207.4%
H
8.2
17.5
|
L
 207.4%
H
8.2
17.5
|
L
 201.4%
H
0
17.5
|
L
 -84.0%
H
0
84
|
L
 -92.7%
H
0
984
|
| Elicio Therapeutics Inc |
|
78.4
|
4.1
|
L
 -0.7%
H
4.0
4.4
|
L
 0.7%
H
2.7
6.6
|
L
 -58.7%
H
2.7
16
|
L
 -62.1%
H
2.7
16
|
L
 -48.9%
H
2.7
16
|
L
 -61.5%
H
2.7
16
|
L
 -96.8%
H
2.7
155.6
|
L
H
2.7
263
|
| Enliven Therapeutics Inc |
|
3,440.5
|
48.2
|
L
 4.8%
H
45.0
48.5
|
L
 13.7%
H
41.0
48.5
|
L
 15.9%
H
33.5
48.5
|
L
 65.9%
H
29.0
48.5
|
L
 126.1%
H
14.8
48.5
|
L
 117.6%
H
9.8
48.5
|
L
 57.6%
H
3.9
48.5
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
682.0
|
11.9
|
L
 -2.2%
H
11.9
12.6
|
L
 3.7%
H
10.7
12.6
|
L
 8.3%
H
10.2
12.6
|
L
 94.9%
H
5.9
12.6
|
L
 884.3%
H
1.2
12.6
|
L
 298.3%
H
1.1
12.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
147.0
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
 -7.6%
H
0.6
0.7
|
L
 -15.3%
H
0.6
0.9
|
L
 -40.2%
H
0.6
1.3
|
L
 -44.0%
H
0.6
2.1
|
L
 -77.5%
H
0.6
4.6
|
L
 -93.4%
H
0.6
14.0
|
L
 -99.1%
H
0.6
81.6
|
| Enochian Biosciences Inc |
|
-
|
4.2
|
L
 9.8%
H
3.1
4.7
|
L
 59%
H
2.5
5.0
|
L
 83.6%
H
2.0
5.0
|
L
 783.0%
H
0.2
5.0
|
L
 1120.6%
H
0.1
5.0
|
L
 558.7%
H
0.1
5.0
|
L
 -25.9%
H
0.1
13.8
|
L
 66%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
4.1
|
0.3
|
L
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 -15.6%
H
0.2
0.3
|
L
 -53.5%
H
0.2
0.6
|
L
 -86.6%
H
0.2
2.8
|
L
 -87.2%
H
0.1
9.9
|
L
 -100.0%
H
0.1
4108.8
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
180.2
|
2.9
|
L
 -0.4%
H
2.8
3.0
|
L
 1.8%
H
2.7
3.2
|
L
 26.1%
H
2.2
3.5
|
L
 33.8%
H
1.6
3.5
|
L
 763.6%
H
0.3
3.5
|
L
 270.1%
H
0.3
3.5
|
L
 -51.7%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Edgewise Therapeutics Inc |
|
4,147.7
|
38.6
|
L
 5.6%
H
36.0
39.3
|
L
 9.5%
H
30.8
39.3
|
L
 17.9%
H
30.8
40.8
|
L
 32.7%
H
28.9
40.8
|
L
 169.6%
H
12.2
40.8
|
L
 392.3%
H
5.1
40.8
|
L
 46.8%
H
5.1
40.8
|
L
H
5.1
40.8
|
| Evaxion Biotech A/S (ADR) |
|
29.2
|
3.5
|
L
 2.3%
H
3.4
3.6
|
L
 -2.8%
H
3.0
3.7
|
L
 -14.2%
H
3.0
4.2
|
L
 -10.5%
H
3.0
4.8
|
L
 50.9%
H
2.3
12.2
|
L
 -71.8%
H
0.8
13.8
|
L
 -94.3%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
249.4
|
2.1
|
L
 -0.5%
H
2.1
2.3
|
L
 6.5%
H
1.9
2.3
|
L
 -4.9%
H
1.8
2.9
|
L
 94.6%
H
1.1
2.9
|
L
 79.8%
H
0.9
2.9
|
L
 -59.3%
H
0.7
8.8
|
L
 -97.4%
H
0.7
97.4
|
L
 16.9%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
371.9
|
18.2
|
L
 -0.7%
H
16.9
19.0
|
L
 0.6%
H
16.9
19.0
|
L
 -15.9%
H
15.5
23.1
|
L
 -22.7%
H
15.5
35.8
|
L
 23.9%
H
9.1
35.8
|
L
 -30.2%
H
4.1
35.8
|
L
 -98.0%
H
4.1
946.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
610.6
|
11.7
|
L
 12.1%
H
10.2
12.2
|
L
 26.7%
H
8.6
12.2
|
L
 35.8%
H
8.4
12.2
|
L
 35.7%
H
8.1
12.2
|
L
 182.8%
H
3.7
12.3
|
L
 -35.5%
H
2.2
36.3
|
L
 -51.2%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Foghorn Therapeutics Inc |
|
246.0
|
4.2
|
L
 0.2%
H
4.1
4.3
|
L
 2.0%
H
4.0
4.3
|
L
 -0.7%
H
3.5
4.6
|
L
 -16.2%
H
3.5
5.6
|
L
 -11.2%
H
3.3
7.0
|
L
 -50.8%
H
2.7
10.2
|
L
 -59.4%
H
2.7
24.3
|
L
H
2.7
28.3
|
| Frequency Therapeutics Inc |
|
-
|
13.9
|
L
 7.0%
H
12.6
14.0
|
L
 19.2%
H
10.6
14.0
|
L
 19.7%
H
10.3
14.0
|
L
 29.3%
H
9.1
15.6
|
L
 12.6%
H
5.2
55.9
|
L
 -18.5%
H
5.2
55.9
|
L
 -97.1%
H
5.2
545
|
L
H
5.2
2918.5
|
| First Wave BioPharma Inc |
|
7.6
|
4.9
|
L
 -10%
H
4.8
5.7
|
L
H
4.8
5.7
|
L
 0.4%
H
4.5
6.9
|
L
 137.1%
H
1.9
6.9
|
L
 817.0%
H
0.4
6.9
|
L
 -85.2%
H
0.4
35
|
L
 -100.0%
H
0.4
35991.6
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
208.8
|
3.2
|
L
 13.2%
H
2.7
3.7
|
L
 21.0%
H
2.5
3.7
|
L
 26.8%
H
2.3
3.7
|
L
 15.3%
H
2.0
3.7
|
L
 31.0%
H
2.0
7.1
|
L
 124.8%
H
0.7
7.1
|
L
 -1.9%
H
0.7
7.1
|
L
 123.2%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
76.8
|
1.8
|
L
 -2.7%
H
1.8
1.9
|
L
 2.9%
H
1.8
2.0
|
L
 1.1%
H
1.6
2.1
|
L
 -7.7%
H
1.5
2.2
|
L
 1.7%
H
1.4
4.3
|
L
 -61.3%
H
0.9
5.3
|
L
 -79.9%
H
0.9
10.8
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
12.0
|
1.0
|
L
 -6.5%
H
1
1.0
|
L
 -12.2%
H
1
1.2
|
L
 -10.6%
H
1.0
1.3
|
L
 -8.2%
H
0.7
1.4
|
L
 -55.7%
H
0.7
3.7
|
L
 -65.3%
H
0.7
9.3
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
866.1
|
1.4
|
L
 0.8%
H
1.3
1.4
|
L
 17.4%
H
1.1
1.4
|
L
 5.5%
H
1.1
1.4
|
L
 -7.5%
H
1.1
1.8
|
L
 -10.6%
H
1.0
2.0
|
L
 -56.7%
H
1.0
5.3
|
L
 -14.0%
H
1.0
5.3
|
L
 -49.4%
H
0.8
7.0
|
| Gilead Sciences |
|
155,643.2
|
125.4
|
L
 0.4%
H
124.4
126.6
|
L
 0.9%
H
122.4
128.2
|
L
 -6.7%
H
121.4
137.2
|
L
 -8.6%
H
121.4
143.0
|
L
 15.5%
H
104.5
157.3
|
L
 60.5%
H
62.1
157.3
|
L
 87.0%
H
57.2
157.3
|
L
 52.0%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
342.3
|
23.3
|
L
 -1.8%
H
22.9
24.0
|
L
 -0.4%
H
22.6
25.5
|
L
 -15.7%
H
20.9
29.9
|
L
 -3.2%
H
20.5
30.3
|
L
 162.0%
H
7.8
34.1
|
L
 129.1%
H
7.6
34.1
|
L
 -39.3%
H
6.8
49.0
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,730.1
|
20.5
|
L
 9.7%
H
18.4
21.0
|
L
 13.0%
H
17.4
21.0
|
L
 8.9%
H
16.1
21.0
|
L
 31.0%
H
14.2
21.6
|
L
 342.3%
H
4.1
25.8
|
L
 200.3%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
6.7
|
1.3
|
L
 -2.3%
H
1.3
1.3
|
L
 9.3%
H
1.1
1.4
|
L
 -64.6%
H
1.1
3.6
|
L
 -12.2%
H
1.0
4.4
|
L
 -94.5%
H
1.0
24.5
|
L
 -99.4%
H
1.0
276.8
|
L
 -99.9%
H
1.0
2812.5
|
L
 -100.0%
H
1.0
379518072.3
|
| Graphite Bio Inc |
|
338.9
|
5.8
|
L
 -5.4%
H
5.7
6.2
|
L
 -12.2%
H
5.7
6.8
|
L
 -22.9%
H
5.7
8.5
|
L
 -44.5%
H
5.7
11.5
|
L
 -80.6%
H
5.7
50.4
|
L
 -95.7%
H
5.7
413
|
L
H
5.7
1666
|
L
H
5.7
1666
|
| Galapagos NV (ADR) |
|
1,907.1
|
28.9
|
L
 2.3%
H
28
29.0
|
L
 1.0%
H
28.0
29.0
|
L
 5.3%
H
26.9
29.3
|
L
 -9.6%
H
26.4
32.4
|
L
 5.5%
H
26.4
37.8
|
L
 -29.7%
H
22.4
44.3
|
L
 -59.7%
H
22.4
72.2
|
L
 -44.9%
H
22.4
274.0
|
| Halozyme Therapeutics Inc |
|
8,221.1
|
69.3
|
L
 0.5%
H
68.9
70.2
|
L
 -2.8%
H
67.0
72.3
|
L
 1.5%
H
65.6
72.3
|
L
 9.3%
H
61.3
73.9
|
L
 31.2%
H
51.1
82.2
|
L
 95.6%
H
32.8
82.2
|
L
 61.0%
H
29.9
82.2
|
L
 703.1%
H
7.7
82.2
|
| HCW Biologics Inc |
|
7.7
|
1.1
|
L
 -6.9%
H
1.1
1.2
|
L
 -11.5%
H
1.0
1.3
|
L
 -62.6%
H
1.0
3.0
|
L
 46.0%
H
0.3
4.0
|
L
 -76.4%
H
0.3
7.4
|
L
 -98.7%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
37.7
|
3.2
|
L
 -4.2%
H
3.1
3.5
|
L
H
3.1
3.8
|
L
 -8.8%
H
2.1
3.8
|
L
 -3.3%
H
2.1
3.9
|
L
 139.6%
H
1.1
9.1
|
L
 -65.9%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
79.5
|
0.4
|
L
 -2.3%
H
0.4
0.4
|
L
 5%
H
0.4
0.5
|
L
 -51.2%
H
0.4
0.9
|
L
 -46.2%
H
0.4
1.3
|
L
 -79%
H
0.4
2.3
|
L
 -64.1%
H
0.4
3.9
|
L
 -97.4%
H
0.4
16.6
|
L
 -97.7%
H
0.4
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
24.6
|
3.9
|
L
 5.2%
H
3.5
4.1
|
L
 4.1%
H
3.5
4.2
|
L
 -58.3%
H
3.5
10.8
|
L
 71.9%
H
2.2
10.8
|
L
 -89%
H
2.1
32.6
|
L
 -95.8%
H
2.1
109.2
|
L
 -96.8%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
188.7
|
0.7
|
L
 -16.7%
H
0.7
0.9
|
L
 -34.6%
H
0.7
1.1
|
L
 -33.3%
H
0.7
1.5
|
L
 -10.3%
H
0.6
1.5
|
L
 -69.7%
H
0.6
2.8
|
L
 -76.1%
H
0.6
10.0
|
L
 -93.1%
H
0.6
17.5
|
L
H
0.6
17.5
|
| Immucell Corp |
|
89.9
|
9.9
|
L
 2.1%
H
9.6
10.0
|
L
 4.3%
H
9.3
10.0
|
L
 -1.8%
H
9.3
10.8
|
L
 63.8%
H
6.2
10.8
|
L
 30.8%
H
4.5
10.8
|
L
 73.2%
H
3.3
10.8
|
L
 1.1%
H
3.3
11.0
|
L
 42%
H
3.3
13.2
|
| InflaRx N.V. |
|
278.4
|
1.9
|
L
 -0.5%
H
1.8
2.0
|
L
 16.7%
H
1.5
2.0
|
L
 -27.6%
H
1.5
2.9
|
L
 101.1%
H
0.8
3.0
|
L
 136.3%
H
0.7
3.0
|
L
 -58.2%
H
0.7
4.6
|
L
 -37%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
67.1
|
6.0
|
L
 -0.7%
H
5.9
6.1
|
L
 7.4%
H
5.4
6.1
|
L
 7.0%
H
5.3
6.1
|
L
 4.6%
H
3.9
6.6
|
L
 -63.5%
H
3.9
18
|
L
 -92.7%
H
3.9
85.1
|
L
 -96.6%
H
3.9
211.2
|
L
H
3.9
451.3
|
| Illumina Inc |
|
24,846.5
|
164.2
|
L
 1.8%
H
160.0
166.6
|
L
 -1.6%
H
157.6
167.4
|
L
 13.7%
H
142.6
177.2
|
L
 32.1%
H
116.7
177.2
|
L
 81.5%
H
88
177.2
|
L
 -18.8%
H
68.7
202.9
|
L
 -64.7%
H
68.7
526
|
L
 16.6%
H
68.7
555.8
|
| Immunome Inc |
|
2,159.7
|
19.1
|
L
 -0.6%
H
19
19.6
|
L
 5.5%
H
17.8
19.7
|
L
 -12.0%
H
17.8
22.8
|
L
 -4.7%
H
17.8
24.9
|
L
 117.9%
H
8.0
27.7
|
L
 256.4%
H
5.2
31.0
|
L
 13.4%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
7.5
|
1.8
|
L
 -1.1%
H
1.7
1.9
|
L
 -8.7%
H
1.7
2.1
|
L
 -19.1%
H
1.7
2.5
|
L
 -38.0%
H
1.7
3.2
|
L
 -88.4%
H
1.7
15.2
|
L
 -91.0%
H
1.7
54.8
|
L
 -99.4%
H
1.7
303.8
|
L
 -100.0%
H
1.7
4410
|
| Immatics N.V |
|
1,368.1
|
10.0
|
L
 2.4%
H
9.7
10.2
|
L
 6.2%
H
9
10.2
|
L
 -13.9%
H
8.8
11.8
|
L
 6.2%
H
8.8
11.9
|
L
 78.4%
H
5.1
12.4
|
L
 -15.1%
H
3.3
13.8
|
L
 -13.7%
H
3.3
16.3
|
L
H
3.3
18.4
|
| Immunovant Inc |
|
7,727.8
|
37.6
|
L
 -1.2%
H
37.4
38.9
|
L
 12.6%
H
32.9
38.9
|
L
 10.2%
H
30.2
38.9
|
L
 63.8%
H
23.1
38.9
|
L
 138.2%
H
14.3
38.9
|
L
 83.6%
H
12.7
45.6
|
L
 239.4%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
14.0
|
1.5
|
L
H
1.4
1.5
|
L
 5.0%
H
1.4
1.5
|
L
 -12.6%
H
1.3
1.9
|
L
 -27%
H
1.3
2
|
L
 -33.0%
H
1.2
2.7
|
L
 -24.0%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
4,381.5
|
92.5
|
L
 -0.9%
H
86.4
98.5
|
L
 -1.1%
H
86.4
99.3
|
L
 -8.7%
H
85.5
108.8
|
L
 51.8%
H
57.3
155.3
|
L
 519.4%
H
14.0
155.3
|
L
 247.3%
H
10.8
155.3
|
L
 268.9%
H
7.7
155.3
|
L
H
7.7
155.3
|
| MiNK Therapeutics Inc |
|
61.4
|
12.3
|
L
 0.6%
H
11.9
12.6
|
L
 -1.8%
H
11.7
12.6
|
L
 13.3%
H
10.1
13.4
|
L
 30.9%
H
8.5
14.9
|
L
 69.7%
H
6.8
76
|
L
 -62.9%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
38.5
|
1.5
|
L
 1.4%
H
1.4
1.5
|
L
 13.3%
H
1.3
1.5
|
L
H
1.2
1.5
|
L
 23.9%
H
1.1
1.8
|
L
 -77.3%
H
1.1
11.6
|
L
 -84.0%
H
1.1
14.7
|
L
 -91.5%
H
1.1
30.4
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
1,973.5
|
4.4
|
L
 8.9%
H
4.0
4.5
|
L
 9.7%
H
3.8
4.5
|
L
 7.5%
H
3.7
4.6
|
L
 19.8%
H
3.2
4.6
|
L
 123.2%
H
1.7
5.6
|
L
 -45.6%
H
1.6
18.3
|
L
 -81.6%
H
1.6
28
|
L
 -43.5%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
427.4
|
2.4
|
L
 3.0%
H
2.2
2.4
|
L
 3.0%
H
2.2
2.4
|
L
 4.9%
H
2.0
2.5
|
L
 -2.1%
H
1.9
2.6
|
L
 308.6%
H
0.4
3.0
|
L
 -32.9%
H
0.3
5.5
|
L
 -90.8%
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,703.3
|
70.8
|
L
 0.0%
H
70.3
72.5
|
L
 1.0%
H
68.1
72.8
|
L
 5.9%
H
64.7
72.8
|
L
 21.7%
H
58.1
72.8
|
L
 37.1%
H
40
99.5
|
L
 30.5%
H
25.6
99.5
|
L
 -27.6%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
276.9
|
0.9
|
L
 3.3%
H
0.9
1.0
|
L
 8.1%
H
0.8
1.0
|
L
 -14.6%
H
0.7
1.3
|
L
 -31.9%
H
0.7
1.8
|
L
 25.3%
H
0.5
3.1
|
L
 -11.3%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,494.4
|
29.4
|
L
 0.1%
H
29.1
30.1
|
L
 2.6%
H
27.6
30.1
|
L
 1.9%
H
27.6
30.1
|
L
 -1.8%
H
27.6
32.8
|
L
 -6.3%
H
27.6
40.7
|
L
 -50.5%
H
23.2
77.0
|
L
 -21.6%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
57.5
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 5.4%
H
0.4
0.4
|
L
 -20.4%
H
0.4
0.5
|
L
 -2.5%
H
0.3
1.1
|
L
 -75.6%
H
0.3
3.5
|
L
 -80%
H
0.3
3.5
|
L
 -90.9%
H
0.3
5
|
L
 -88.5%
H
0.3
8.0
|
| Inventiva (ADR) |
|
866.9
|
3.7
|
L
 4.6%
H
3.6
3.7
|
L
 -2.4%
H
3.5
3.7
|
L
 -27.6%
H
3.5
5.5
|
L
 -36.5%
H
3.5
6.2
|
L
 11.6%
H
2.9
8.0
|
L
 -17.5%
H
1.5
8.0
|
L
 -73.7%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
906.8
|
14.9
|
L
 3.7%
H
14.3
15.0
|
L
 8.2%
H
13.6
15.0
|
L
 2.4%
H
13.0
15.0
|
L
 5.8%
H
13.0
16.6
|
L
 -37.0%
H
12.1
35.3
|
L
 22.7%
H
5.7
71.7
|
L
 -32.5%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
13.4
|
0.5
|
L
 -4%
H
0.5
0.5
|
L
H
0.4
0.6
|
L
 -46.7%
H
0.4
1.0
|
L
 -61.0%
H
0.4
1.2
|
L
 -90.7%
H
0.4
7.2
|
L
 -64.7%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kamada Ltd |
|
411.9
|
7.1
|
L
 -0.7%
H
7.0
7.2
|
L
 -4.3%
H
7.0
7.5
|
L
 -8.8%
H
7.0
8.1
|
L
 -13.5%
H
7.0
8.7
|
L
 -0.8%
H
6.5
9.4
|
L
 30.8%
H
4.1
9.4
|
L
 23.1%
H
3.7
9.4
|
L
 93.0%
H
3.6
13.3
|
| Kodiak Sciences Inc |
|
2,369.8
|
37.9
|
L
 3.4%
H
36.0
38.6
|
L
 11.2%
H
32.6
38.6
|
L
 4.5%
H
29.2
38.6
|
L
 70.2%
H
21
47.8
|
L
 946.1%
H
3.5
47.8
|
L
 447.3%
H
1.4
47.8
|
L
 -55.5%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
9,956.5
|
337.7
|
L
 -1.7%
H
337.6
346.8
|
L
 4%
H
321.1
356.5
|
L
 12.8%
H
285.1
356.5
|
L
 34.2%
H
242
356.5
|
L
 155.0%
H
130.5
356.5
|
L
 181.6%
H
94.0
356.5
|
L
 415.6%
H
38.9
356.5
|
L
H
8.0
356.5
|
| TuHURA Biosciences Inc |
|
170.0
|
2.7
|
L
 -1.5%
H
2.6
2.8
|
L
 17.6%
H
2.2
2.8
|
L
 6.8%
H
1.9
2.8
|
L
 37.6%
H
1.3
3.4
|
L
 4.7%
H
0.4
3.9
|
L
 -97.7%
H
0.2
196
|
L
 -99.9%
H
0.2
4987.5
|
L
 -100.0%
H
0.2
173250
|
| Kura Oncology Inc |
|
927.7
|
10.5
|
L
 0.9%
H
10.2
10.7
|
L
 9.5%
H
9.2
10.7
|
L
 -7.1%
H
8.4
11.4
|
L
 26.5%
H
7.5
11.5
|
L
 78.6%
H
5.5
12.5
|
L
 -3.8%
H
5.4
24.2
|
L
 -51.5%
H
5.4
24.2
|
L
 294.3%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
7,991.3
|
97.2
|
L
 -2.3%
H
94.6
100.7
|
L
 13.5%
H
84.5
105
|
L
 23.2%
H
69.5
105
|
L
 24.7%
H
69.5
105
|
L
 111.8%
H
36.7
105
|
L
 314.6%
H
9.6
105
|
L
 118.4%
H
9.6
105
|
L
H
9.6
105
|
| Longeveron Inc (Class A) |
|
25.6
|
0.8
|
L
 1.3%
H
0.8
0.9
|
L
 2.5%
H
0.8
0.9
|
L
 -1.2%
H
0.7
0.9
|
L
 -17.4%
H
0.7
1.2
|
L
 -32.5%
H
0.5
1.8
|
L
 -97.8%
H
0.5
43.0
|
L
 -98.9%
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
124.1
|
7.1
|
L
 -4.6%
H
7.1
7.4
|
L
 6.3%
H
6.3
7.8
|
L
 21.4%
H
5.5
7.8
|
L
 160.6%
H
2.5
7.8
|
L
 815.4%
H
0.7
7.8
|
L
 34.5%
H
0.6
9.5
|
L
 -75.3%
H
0.6
49.5
|
L
 -40.5%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
69.2
|
0.7
|
L
 -12.2%
H
0.6
0.7
|
L
 -19.8%
H
0.6
0.8
|
L
 -45.8%
H
0.5
1.4
|
L
 -7.1%
H
0.5
1.4
|
L
 71.1%
H
0.2
3.7
|
L
 -84.5%
H
0.2
5
|
L
 -96.1%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
379.2
|
3.7
|
L
 -0.3%
H
3.6
3.9
|
L
 1.7%
H
3.4
3.9
|
L
 5.8%
H
3.0
3.9
|
L
 -18.7%
H
3.0
5.4
|
L
 40.9%
H
2.2
6.4
|
L
 8.6%
H
1.6
13.7
|
L
 -54.9%
H
1.5
15.3
|
L
 -95.0%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
292.8
|
12.6
|
L
 4.9%
H
11.7
13.0
|
L
 -7.4%
H
11.7
13.5
|
L
 -28.1%
H
11.7
17.7
|
L
 -34.4%
H
11.7
25.3
|
L
 44.4%
H
8.5
45
|
L
 -80.9%
H
7.7
68.2
|
L
 -96.2%
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
120.9
|
1.8
|
L
 -2.7%
H
1.8
1.9
|
L
 -1.1%
H
1.8
1.9
|
L
 5.3%
H
1.7
2.2
|
L
 -29.1%
H
1.7
2.8
|
L
 -25.3%
H
1.6
4.7
|
L
 -43.6%
H
0.8
4.7
|
L
 -76.7%
H
0.8
9.6
|
L
 -97.1%
H
0.8
403.7
|
| Seres Therapeutics Inc |
|
68.3
|
7.1
|
L
 6.8%
H
6.7
7.4
|
L
 25.4%
H
5.4
7.4
|
L
 -11.0%
H
5.3
8.1
|
L
 -17.1%
H
5.3
9.6
|
L
 -4.7%
H
5.3
30.0
|
L
 29.1%
H
0.4
30.0
|
L
 -69.8%
H
0.4
30.0
|
L
 -76.0%
H
0.4
38.5
|
| MeiraGTx Holdings PLC |
|
1,083.5
|
11.7
|
L
 1.9%
H
11.3
11.9
|
L
 20%
H
9.5
11.9
|
L
 26.6%
H
8.9
11.9
|
L
 62.5%
H
7.0
11.9
|
L
 84.5%
H
6.1
11.9
|
L
 70.3%
H
3.5
11.9
|
L
 -24.2%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,254.2
|
25.6
|
L
 0.8%
H
24.6
26.3
|
L
 6.9%
H
23.3
26.3
|
L
 -14.3%
H
22.3
32.1
|
L
 6.2%
H
22.3
32.1
|
L
 89.7%
H
12.6
47.7
|
L
 58.9%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
554.3
|
82.8
|
L
 20.5%
H
68.2
83.6
|
L
 34.6%
H
60.5
83.6
|
L
 31.1%
H
57.7
83.6
|
L
 49.9%
H
50.1
83.6
|
L
 151.8%
H
29.2
105
|
L
 1780.7%
H
1.4
105
|
L
 180.5%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
23.0
|
1.4
|
L
 0.7%
H
1.4
1.4
|
L
 2.2%
H
1.3
1.4
|
L
 -1.4%
H
1.3
1.6
|
L
 3.0%
H
1.2
1.8
|
L
 -4.8%
H
0.8
4.1
|
L
 -67.1%
H
0.8
9.7
|
L
 -95.5%
H
0.7
32.4
|
L
 -97.8%
H
0.7
135.5
|
| Moderna |
|
24,442.0
|
61.6
|
L
 3.8%
H
58.3
64.0
|
L
 18.2%
H
51.7
67.7
|
L
 31.4%
H
43.9
67.7
|
L
 19.9%
H
43.7
67.7
|
L
 137.8%
H
22.3
67.7
|
L
 -48.9%
H
22.3
170.5
|
L
 -72.2%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
784.7
|
5.3
|
L
 1.3%
H
5.2
5.4
|
L
 7.3%
H
4.9
5.4
|
L
 20.9%
H
4.3
5.4
|
L
 78.5%
H
2.8
5.4
|
L
 158.3%
H
2.0
5.4
|
L
 -60.3%
H
1.7
13.5
|
L
 -88.2%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
127.5
|
1.2
|
L
 0.9%
H
1.2
1.2
|
L
 2.6%
H
1.1
1.2
|
L
 14.4%
H
1.0
1.3
|
L
 56.6%
H
0.7
1.3
|
L
 -41.7%
H
0.6
2.4
|
L
 -74.0%
H
0.6
5.5
|
L
 -79.7%
H
0.6
17.4
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
34.6
|
1.5
|
L
 -1.3%
H
1.5
1.6
|
L
 -28.3%
H
1.5
2.1
|
L
 -54.4%
H
1.5
4.0
|
L
 186.8%
H
0.3
4.9
|
L
 6.3%
H
0.3
4.9
|
L
 -99.2%
H
0.3
200.4
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
1,989.7
|
15.4
|
L
 -0.7%
H
15.1
15.6
|
L
 11.9%
H
13.7
15.7
|
L
 1.3%
H
13.7
15.7
|
L
 7.2%
H
13.3
16.9
|
L
 47.4%
H
9.9
21.5
|
L
 266.4%
H
1.0
22
|
L
 79.2%
H
1.0
22
|
L
 296.6%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
142.9
|
3.8
|
L
 -3.5%
H
3.8
4.0
|
L
 -1.0%
H
3.7
4.1
|
L
 -8.9%
H
3.7
4.2
|
L
 -16.8%
H
3.7
4.6
|
L
 -2.1%
H
3.4
5.4
|
L
 -38.6%
H
3.3
12.7
|
L
 -80.4%
H
3.3
32.0
|
L
 -84.0%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
51.1
|
0.3
|
L
H
0.3
0.3
|
L
 6.7%
H
0.3
0.3
|
L
 14.3%
H
0.3
0.4
|
L
 -5.9%
H
0.2
0.4
|
L
 -88.8%
H
0.2
3.1
|
L
 -75.6%
H
0.2
5.0
|
L
 -89.5%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
298.6
|
2.4
|
L
 1.7%
H
2.3
2.4
|
L
 4.4%
H
2.1
2.4
|
L
 -7.5%
H
2.1
2.9
|
L
 -22.4%
H
2.1
4.3
|
L
 226.4%
H
0.6
4.3
|
L
 -39.1%
H
0.6
4.3
|
L
 -75.0%
H
0.6
12.4
|
L
H
0.6
25.9
|
| Nkarta Inc |
|
217.5
|
3.0
|
L
 9.0%
H
2.7
3.2
|
L
 11.0%
H
2.6
3.2
|
L
 0.3%
H
2.3
3.3
|
L
 42.1%
H
2.0
3.7
|
L
 71.8%
H
1.6
3.7
|
L
 -33.5%
H
1.3
16.2
|
L
 -88.8%
H
1.3
40.6
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
32.3
|
L
 2.3%
H
31.5
33.0
|
L
 8%
H
28.3
33.0
|
L
 16.4%
H
24.9
33.0
|
L
 69.3%
H
18.8
34.0
|
L
 81.6%
H
14.7
37.3
|
L
 112.2%
H
12.2
37.3
|
L
 -83.9%
H
7.5
211.2
|
L
 -74.6%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
8.9
|
L
 -2.1%
H
8.9
9.2
|
L
 -3.7%
H
8.9
9.4
|
L
 0.5%
H
8.8
9.5
|
L
 21.6%
H
7.0
9.5
|
L
 38.0%
H
6.2
9.5
|
L
 1234.3%
H
0.0
9.5
|
L
 -67.6%
H
0.0
29.2
|
L
H
0.0
1010
|
| MetaVia Inc |
|
7.9
|
1.5
|
L
 -2.6%
H
1.5
1.6
|
L
 -10.5%
H
1.5
1.7
|
L
 -60.3%
H
1.5
3.8
|
L
 8.5%
H
1.0
4.3
|
L
 -79.4%
H
1.0
19.0
|
L
 -95.6%
H
1.0
74.3
|
L
 -100.0%
H
1.0
14863.2
|
L
H
1.0
1424940
|
| Intellia Therapeutics Inc |
|
2,112.6
|
15.1
|
L
 -4%
H
15.1
15.9
|
L
 1.3%
H
13.5
16.7
|
L
 20%
H
11.8
16.7
|
L
 17.8%
H
11.6
17.0
|
L
 64.4%
H
8.0
28.3
|
L
 -64.0%
H
5.9
46.5
|
L
 -80.8%
H
5.9
202.7
|
L
 -43.0%
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
9,767.6
|
123.4
|
L
 0.0%
H
123.4
123.5
|
L
 0.1%
H
123.3
123.6
|
L
 20.9%
H
87.3
123.6
|
L
 30.3%
H
87.3
123.6
|
L
 64.6%
H
71.1
123.6
|
L
 193.4%
H
38.8
123.6
|
L
H
7.1
123.6
|
L
H
7.1
123.6
|
| Novavax Inc |
|
1,499.7
|
9.1
|
L
 1.3%
H
8.8
9.6
|
L
 -1.0%
H
8.8
10.0
|
L
 -1.0%
H
8.4
11.6
|
L
 -5.2%
H
7.6
11.6
|
L
 42.3%
H
6.1
12.0
|
L
 27.4%
H
3.5
23.9
|
L
 -95.3%
H
3.5
277.8
|
L
 -93.2%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
7.2
|
1.7
|
L
 -5.5%
H
1.7
2.0
|
L
 -9.9%
H
1.7
2.0
|
L
 -14.4%
H
1.7
2.4
|
L
 4.9%
H
1.3
2.4
|
L
 -100.0%
H
1.3
5120
|
L
 -100.0%
H
1.3
950000
|
L
 -100.0%
H
1.3
3319720
|
L
H
1.3
32000000
|
| Insight Molecular Diagnostics Inc |
|
174.7
|
5.4
|
L
 0.2%
H
5.2
5.6
|
L
 -5.1%
H
4.6
5.7
|
L
 -11.2%
H
4.6
6.9
|
L
 27%
H
2.4
6.9
|
L
 27.6%
H
2.3
8.5
|
L
 28.8%
H
1.9
8.5
|
L
 -95.1%
H
1.9
125
|
L
 -93.0%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
84.5
|
1.6
|
L
 2.6%
H
1.5
1.6
|
L
 5.9%
H
1.5
1.6
|
L
 -1.2%
H
1.4
1.8
|
L
 2.6%
H
1.4
1.8
|
L
 -32.1%
H
1.4
3.4
|
L
 33.1%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
114.6
|
1.0
|
L
 4.4%
H
0.9
1.0
|
L
 12.9%
H
0.9
1.0
|
L
 18.5%
H
0.8
1.2
|
L
 1.1%
H
0.8
1.2
|
L
 39.1%
H
0.6
1.5
|
L
 -61.9%
H
0.3
3.4
|
L
 -66.4%
H
0.3
3.4
|
L
 -73.6%
H
0.3
8.5
|
| Traws Pharma Inc |
|
12.9
|
0.9
|
L
 -4.5%
H
0.9
0.9
|
L
 11.8%
H
0.8
0.9
|
L
 -43.0%
H
0.6
1.7
|
L
 -60.3%
H
0.6
3.2
|
L
 -49.1%
H
0.6
3.3
|
L
 -96.9%
H
0.6
29.5
|
L
 -99.5%
H
0.6
188
|
L
 -100.0%
H
0.6
36112.5
|
| VivoSim Labs Inc |
|
3.2
|
1.1
|
L
 -2.7%
H
1.1
1.2
|
L
 -9.1%
H
1.1
1.2
|
L
 -19.1%
H
1.1
1.4
|
L
 -34.5%
H
1.1
1.9
|
L
 -24.7%
H
1.1
5.3
|
L
 -94.7%
H
0.3
24.6
|
L
 -98.9%
H
0.3
118.7
|
L
 -99.9%
H
0.3
1197.6
|
| Passage Bio Inc |
|
20.0
|
6.2
|
L
 8.7%
H
5.5
6.2
|
L
 13.1%
H
5.3
6.2
|
L
 19.2%
H
4.9
6.2
|
L
 -16.3%
H
3.9
12.1
|
L
 -20.5%
H
3.9
20
|
L
 -62.5%
H
3.9
35.8
|
L
 -97.7%
H
3.9
322.8
|
L
H
3.9
764.6
|
| Vaxcyte Inc |
|
7,588.1
|
52.6
|
L
 0.8%
H
51.5
53.3
|
L
 6.0%
H
48.9
53.5
|
L
 11.1%
H
45.3
53.5
|
L
 -4.0%
H
45.3
63.3
|
L
 59.9%
H
29.1
65
|
L
 -2.8%
H
27.7
121.1
|
L
 146.3%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
125.9
|
1.8
|
L
 -0.6%
H
1.8
1.9
|
L
 19.0%
H
1.6
2.0
|
L
 20.5%
H
1.3
2.0
|
L
 -61.3%
H
1.3
5.4
|
L
 25.5%
H
1.0
7.8
|
L
 -81.1%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,885.9
|
5.3
|
L
 -1.7%
H
5.3
5.6
|
L
 10.2%
H
4.6
5.6
|
L
 24.8%
H
3.5
5.6
|
L
 61.3%
H
3.0
5.6
|
L
 264.8%
H
1.4
5.6
|
L
 360%
H
0.7
5.6
|
L
 -16.0%
H
0.7
7.0
|
L
 -78.5%
H
0.7
32.9
|
| Phio Pharma Corp |
|
12.1
|
1.0
|
L
 -1.0%
H
1.0
1.1
|
L
 -5.5%
H
1.0
1.1
|
L
 -4.6%
H
1.0
1.1
|
L
 -14.8%
H
1.0
1.4
|
L
 -54.0%
H
0.8
4.2
|
L
 -96.1%
H
0.6
29.1
|
L
 -99.6%
H
0.6
266.8
|
L
 -100.0%
H
0.6
194238
|
| Pliant Therapeutics Inc |
|
71.8
|
1.2
|
L
H
1.2
1.2
|
L
 1.8%
H
1.1
1.2
|
L
 -4.1%
H
1.1
1.3
|
L
 -10.1%
H
1.1
1.4
|
L
 -9.4%
H
1.1
2.0
|
L
 -94.5%
H
1.1
21.2
|
L
 -95.9%
H
1.1
36.6
|
L
H
1.1
43.9
|
| Pluri Inc |
|
21.6
|
2
|
L
 -1.0%
H
2
2.1
|
L
 -14.2%
H
2
2.4
|
L
 -15.6%
H
2
2.6
|
L
 -35.7%
H
2
3.9
|
L
 -49.5%
H
2
6.0
|
L
 -69.1%
H
0.7
8.6
|
L
 -93.6%
H
0.7
33.7
|
L
 -98.1%
H
0.7
169.6
|
| Prelude Therapeutics Inc |
|
336.1
|
4.2
|
L
 -2.3%
H
4.1
4.4
|
L
 -5.4%
H
4.1
4.6
|
L
 -1.2%
H
3.4
4.7
|
L
 41.1%
H
2.9
5.5
|
L
 390.7%
H
0.8
5.5
|
L
 -15.6%
H
0.6
6.8
|
L
 -87.2%
H
0.6
43.6
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
596.0
|
3.3
|
L
 -2.1%
H
3.3
3.5
|
L
 13.8%
H
2.8
3.6
|
L
 11.1%
H
2.7
3.6
|
L
 -6.3%
H
2.7
4.0
|
L
 59.4%
H
2.0
6.9
|
L
 -77.9%
H
1.1
15.8
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
359.1
|
1.8
|
L
 -3.9%
H
1.7
1.9
|
L
 4.8%
H
1.6
1.9
|
L
H
1.6
2.0
|
L
 -9.3%
H
1.5
2.2
|
L
 165.2%
H
0.5
7.1
|
L
 -84.2%
H
0.5
13.5
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
500.0
|
9.6
|
L
 4.4%
H
9.1
9.8
|
L
 17.2%
H
7.9
9.8
|
L
 -2.9%
H
7.7
10.3
|
L
 9.1%
H
7.7
11.8
|
L
 67.0%
H
5.7
11.8
|
L
 -86.5%
H
4.3
73.1
|
L
 -78.9%
H
4.3
79.8
|
L
 -75.0%
H
4.3
79.8
|
| Alpha Compute Corp |
|
6.6
|
0.3
|
L
H
0.3
0.3
|
L
 3.7%
H
0.2
0.3
|
L
 -22.2%
H
0.2
0.6
|
L
 -20%
H
0.2
0.6
|
L
 -95.0%
H
0.2
13.8
|
L
 -99.6%
H
0.2
79
|
L
 -100.0%
H
0.2
720.4
|
L
 -99.9%
H
0.2
1310
|
| Protagonist Therapeutics Inc |
|
7,587.5
|
118.0
|
L
 2.6%
H
114.6
119.9
|
L
 4.9%
H
108.5
119.9
|
L
 18.9%
H
92.8
119.9
|
L
 19.3%
H
92.8
119.9
|
L
 121.2%
H
49.4
119.9
|
L
 328.4%
H
13.7
119.9
|
L
 171.8%
H
6.9
119.9
|
L
H
4.5
119.9
|
| Quince Therapeutics Inc |
|
19.0
|
1.0
|
L
 4.3%
H
0.9
1
|
L
 4.3%
H
0.9
1.0
|
L
 -11.8%
H
0.9
1.3
|
L
 21.3%
H
0.8
3.8
|
L
 -92.5%
H
0.8
45.5
|
L
 -93.2%
H
0.8
45.5
|
L
 -99.8%
H
0.8
1219.8
|
L
H
0.8
1219.8
|
| uniQure NV |
|
3,023.5
|
47.9
|
L
 8%
H
44.5
48.8
|
L
 72.0%
H
26.7
50.1
|
L
 98.2%
H
24
50.1
|
L
 198.0%
H
13.2
50.1
|
L
 237.4%
H
8.7
71.5
|
L
 330.3%
H
3.7
71.5
|
L
 57.0%
H
3.7
71.5
|
L
 522.6%
H
3.7
82.5
|
| Rain Oncology Inc |
|
72.0
|
2.0
|
L
 6.5%
H
1.8
2
|
L
 -13.5%
H
1.6
2.6
|
L
 -16.8%
H
1.6
2.6
|
L
 -34.7%
H
1.3
3.2
|
L
 -31.3%
H
1.3
8.5
|
L
 54.7%
H
0.8
9.2
|
L
 -87.7%
H
0.8
22.2
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
85.4
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 -1.3%
H
0.7
0.8
|
L
 -29.0%
H
0.7
1.0
|
L
 -32.7%
H
0.7
1.2
|
L
 52%
H
0.4
3.9
|
L
 -82.3%
H
0.4
8.8
|
L
 -99.6%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
384.4
|
3.5
|
L
 1.7%
H
3.4
3.6
|
L
 23.1%
H
2.8
3.6
|
L
 18.9%
H
2.5
3.6
|
L
 -15.0%
H
2.5
5.1
|
L
 30.4%
H
2.4
5.5
|
L
 -83.7%
H
2.2
32.5
|
L
 -91.7%
H
2.2
49.7
|
L
 -88.1%
H
2.2
67.5
|
| Replimune Grp Inc |
|
933.1
|
11.3
|
L
 1.1%
H
10.9
12.2
|
L
 26.1%
H
8.6
12.2
|
L
 130.1%
H
4.5
12.2
|
L
 61.9%
H
1.5
12.2
|
L
 21.9%
H
1.5
13.2
|
L
 -52.0%
H
1.5
24.3
|
L
 -67.9%
H
1.5
40.2
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
4.1
|
1.0
|
L
 -1.0%
H
1.0
1.1
|
L
 5.1%
H
1.0
1.1
|
L
 -2.8%
H
1.0
1.1
|
L
 -12.6%
H
0.9
1.3
|
L
 -88.4%
H
0.9
12.9
|
L
 -100.0%
H
0.9
6048
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Relay Therapeutics Inc |
|
3,807.4
|
17.5
|
L
 1.1%
H
16.6
17.7
|
L
 16.8%
H
14.8
17.7
|
L
 29.1%
H
12.9
17.7
|
L
 76.3%
H
9.3
17.7
|
L
 447.7%
H
3.0
17.7
|
L
 46.8%
H
1.8
17.7
|
L
 -49.5%
H
1.8
38.6
|
L
H
1.8
64.4
|
| TransCode Therapeutics Inc |
|
4.6
|
4.9
|
L
 -2.4%
H
4.6
4.9
|
L
 -10.8%
H
4.4
5.9
|
L
 -21.8%
H
3.8
6.3
|
L
 -45.7%
H
3.8
10.3
|
L
 -35.5%
H
3.8
21.0
|
L
 -100.0%
H
3.8
118272
|
L
H
3.8
5174400
|
L
H
3.8
5174400
|
| Recursion Pharma Inc (Class A) |
|
1,671.9
|
3.2
|
L
 -0.9%
H
3.1
3.3
|
L
 -4.3%
H
3.1
3.3
|
L
 4.7%
H
2.9
4.0
|
L
 -3.1%
H
2.8
4.0
|
L
 -37.4%
H
2.8
7.2
|
L
 -59.1%
H
2.8
16.7
|
L
 -91.2%
H
2.8
42.8
|
L
H
2.8
42.8
|
| Rhythm Pharma Inc |
|
7,209.2
|
105.1
|
L
 3.7%
H
99.5
106.2
|
L
 17.2%
H
88.5
106.2
|
L
 19.7%
H
82.9
106.2
|
L
 20.2%
H
74.5
106.2
|
L
 69.5%
H
60.8
122.2
|
L
 458.4%
H
15.5
122.2
|
L
 411.2%
H
3.0
122.2
|
L
H
3.0
122.2
|
| SAB Biotherapeutics Inc |
|
297.4
|
3.9
|
L
 -1.0%
H
3.8
4
|
L
 -0.3%
H
3.7
4.1
|
L
 -0.3%
H
3.3
4.2
|
L
 3.7%
H
3.3
4.6
|
L
 117.3%
H
1.7
6.6
|
L
 352.3%
H
0.4
6.6
|
L
 -61.0%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
923.9
|
3.3
|
L
 -1.2%
H
3.3
3.5
|
L
 16.5%
H
2.8
3.5
|
L
 8.1%
H
2.6
3.5
|
L
 6.8%
H
2.6
4.1
|
L
 27.2%
H
2.6
6.6
|
L
 -40.9%
H
1.3
12
|
L
 -83.3%
H
1.3
26.6
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
58.0
|
1.2
|
L
 -3.2%
H
1.2
1.3
|
L
 -0.8%
H
1.2
1.3
|
L
 -8.4%
H
1.2
1.6
|
L
 -33.0%
H
1.2
1.9
|
L
 -39.7%
H
1.2
5.0
|
L
 -95.3%
H
1.2
42.2
|
L
 -98.5%
H
1.2
146.2
|
L
 -91.6%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
95.7
|
1.7
|
L
 -1.1%
H
1.7
1.8
|
L
 1.8%
H
1.7
1.8
|
L
 -2.8%
H
1.7
1.9
|
L
 3.6%
H
1.7
2.1
|
L
 -13.4%
H
1.7
2.4
|
L
 -61.4%
H
1.5
5.7
|
L
 -94.8%
H
1.5
45.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,540.8
|
10.0
|
L
 3.3%
H
9.6
10.3
|
L
 15.7%
H
8.4
10.6
|
L
 47.4%
H
5.8
10.6
|
L
 52.8%
H
5.6
10.6
|
L
 2.0%
H
5.6
15.6
|
L
 -3.0%
H
5.6
15.6
|
L
 -3.0%
H
5.6
15.6
|
L
 -3.0%
H
5.6
15.6
|
| Solid Biosciences Inc |
|
856.5
|
8.7
|
L
 4.8%
H
8.1
9.2
|
L
 18.2%
H
7.0
9.2
|
L
 31.4%
H
6.3
9.2
|
L
 23.8%
H
6
9.2
|
L
 81.6%
H
3.8
9.2
|
L
 57.6%
H
1.8
15.1
|
L
 -84.6%
H
1.8
62.1
|
L
H
1.8
822.6
|
| Summit Therapeutics Inc |
|
11,052.6
|
14.2
|
L
 -0.3%
H
13.9
14.8
|
L
 0.8%
H
13.6
14.8
|
L
 -14.3%
H
12.6
18.5
|
L
 -8.2%
H
12.6
29.2
|
L
 -30.7%
H
12.6
31.0
|
L
 412.2%
H
1.5
36.9
|
L
 117.1%
H
0.7
36.9
|
L
 78%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,737.6
|
19.6
|
L
 1.5%
H
19.2
20
|
L
 6.1%
H
18.3
20.4
|
L
 -1.7%
H
16.7
20.4
|
L
 -19.1%
H
16.7
25.6
|
L
 106.9%
H
8.6
25.6
|
L
 -8.0%
H
8.6
25.6
|
L
 10.2%
H
8.6
29.9
|
L
 72.5%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
623.6
|
24.2
|
L
 4.3%
H
22.8
29.0
|
L
 74.7%
H
13.4
29.0
|
L
 36.0%
H
10.8
29.0
|
L
 -23.4%
H
10.8
36.1
|
L
 215.8%
H
6.3
36.8
|
L
 -9.7%
H
5
38.8
|
L
 -89.1%
H
5
247.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
29.3
|
0.9
|
L
 -4.1%
H
0.9
1.0
|
L
 -3.1%
H
0.9
1.0
|
L
 -5.1%
H
0.9
1.1
|
L
 2.2%
H
0.8
1.2
|
L
 -55.9%
H
0.8
2.9
|
L
 -90.6%
H
0.8
16.9
|
L
 -6%
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
148.6
|
54.0
|
L
 -1.3%
H
53.3
55.1
|
L
 8.2%
H
46.5
56.0
|
L
 5.7%
H
46.5
56.0
|
L
 -7.6%
H
46.5
80
|
L
 514.2%
H
7.3
240
|
L
 -67.3%
H
4.3
446.3
|
L
 -93.2%
H
4.3
863.3
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
125.6
|
2.2
|
L
 -1.8%
H
2.2
2.2
|
L
 -25.4%
H
2.0
3.1
|
L
 -21.4%
H
2.0
3.1
|
L
 -8.4%
H
2.0
3.1
|
L
 -28.2%
H
1.8
3.2
|
L
 47.6%
H
0.5
3.2
|
L
 -84.8%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
6,118.4
|
51.1
|
L
 3.8%
H
49.0
51.6
|
L
 11.2%
H
44.5
51.6
|
L
 6.1%
H
43.2
52.2
|
L
 14.4%
H
40.2
52.2
|
L
 50%
H
27.1
52.2
|
L
 463.6%
H
5.9
52.2
|
L
 70.3%
H
4.3
52.2
|
L
H
4.3
70
|
| Surrozen Inc |
|
284.5
|
24.5
|
L
 3.6%
H
22.8
24.6
|
L
 5.9%
H
22.0
25.6
|
L
 -7.1%
H
20.5
27.1
|
L
 -2.6%
H
20.5
35
|
L
 145.3%
H
8
35
|
L
 3669.2%
H
0.3
35
|
L
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,943.2
|
31.2
|
L
 0.7%
H
30.7
32.4
|
L
 4%
H
29.0
32.4
|
L
 6.3%
H
28.1
32.4
|
L
 -6.9%
H
28.0
37.4
|
L
 169.4%
H
11.2
40.2
|
L
 137.6%
H
3.4
40.2
|
L
 -13.6%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
506.2
|
5.3
|
L
 1.2%
H
5.1
5.5
|
L
 14.5%
H
4.3
5.5
|
L
 -13.1%
H
3.3
6.3
|
L
 -14.8%
H
3.3
8.3
|
L
 452.1%
H
0.7
8.3
|
L
 54.1%
H
0.7
11.8
|
L
 -82.0%
H
0.7
30.1
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
4.5
|
1.7
|
L
 0.6%
H
1.7
1.8
|
L
 14.1%
H
1.4
1.8
|
L
 14.9%
H
1.2
1.8
|
L
 -12.8%
H
1.2
2.4
|
L
 -79.5%
H
1.2
10.8
|
L
H
1.2
2076
|
L
H
1.2
2076
|
L
H
1.2
2076
|
| Alaunos Therapeutics Inc |
|
5.3
|
2.2
|
L
 -0.5%
H
2.2
2.2
|
L
 -5.7%
H
2.2
2.3
|
L
 -11.2%
H
1.9
3.1
|
L
 -33.2%
H
1.9
3.3
|
L
 -49.9%
H
1.7
6.2
|
L
 377.8%
H
0.0
6.2
|
L
 -18.3%
H
0.0
6.2
|
L
 -63.2%
H
0.0
7.9
|
| Tscan Therapeutics Inc |
|
60.8
|
0.9
|
L
 8.1%
H
0.9
1.0
|
L
 -2.1%
H
0.9
1.0
|
L
 -12.3%
H
0.9
1.1
|
L
 -10.6%
H
0.9
1.5
|
L
 -35.4%
H
0.9
2.6
|
L
 -67.1%
H
0.9
9.7
|
L
H
0.9
14.7
|
L
H
0.9
14.7
|
| Bio-Techne |
|
8,849.3
|
56.5
|
L
 1.6%
H
55.8
57.3
|
L
 0.6%
H
54.3
58.6
|
L
 17.2%
H
47.1
58.6
|
L
 9.8%
H
43.2
62.5
|
L
 13.3%
H
43.2
72.2
|
L
 -26.1%
H
43.2
89.9
|
L
 -48.8%
H
43.2
136.0
|
L
 103.3%
H
23.9
136.0
|
| Instil Bio Inc |
|
51.7
|
7.6
|
L
 0.9%
H
7.6
7.9
|
L
 -3.7%
H
7.5
7.9
|
L
 -6.7%
H
7.5
8.3
|
L
 -10.8%
H
7.5
9
|
L
 -72.5%
H
5.7
33.8
|
L
 1396.1%
H
0.3
92
|
L
 -57.9%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
4,628.8
|
28.4
|
L
 -0.3%
H
28.0
29.1
|
L
 -13.6%
H
27.7
34.4
|
L
 40.5%
H
19.4
34.4
|
L
 46.4%
H
18.5
34.4
|
L
 451.0%
H
4.6
34.4
|
L
 724.1%
H
1.0
34.4
|
L
H
1.0
34.4
|
L
H
1.0
34.4
|
| Entrada Therapeutics Inc |
|
279.1
|
7.2
|
L
 1.7%
H
6.8
7.4
|
L
 9.3%
H
6.4
7.4
|
L
 9.6%
H
5.8
7.4
|
L
 -36.4%
H
5.6
16.5
|
L
 1.0%
H
4.9
16.5
|
L
 -55.0%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
2,483.2
|
17.5
|
L
 -1.2%
H
17.3
18.2
|
L
 19.3%
H
14.2
18.2
|
L
 23.8%
H
13.2
18.2
|
L
 64.8%
H
10.3
18.2
|
L
 193.5%
H
5.4
18.2
|
L
 533.7%
H
1.0
18.2
|
L
 753.2%
H
0.5
18.2
|
L
H
0.5
18.2
|
| Taysha Gene Therapies Inc |
|
1,977.0
|
6.9
|
L
 5.4%
H
6.5
7.1
|
L
 15.2%
H
5.6
7.1
|
L
 25.3%
H
5.3
7.1
|
L
 56.4%
H
4.0
7.3
|
L
 179.7%
H
2.3
7.3
|
L
 855.6%
H
0.5
7.3
|
L
 -72.8%
H
0.5
26.9
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
5,305.5
|
85.2
|
L
 0.0%
H
81.6
87.5
|
L
 5.5%
H
80.6
89.7
|
L
 40.7%
H
60.6
89.7
|
L
 102.5%
H
42.7
89.7
|
L
 146.0%
H
23.3
89.7
|
L
 380.8%
H
14.4
89.7
|
L
 -28.3%
H
11.5
140.0
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
4,047.4
|
31.9
|
L
 -3.2%
H
31.3
33.4
|
L
 -1.1%
H
31.3
36.6
|
L
 34.6%
H
23.0
36.6
|
L
 73.4%
H
18.3
36.6
|
L
 194.9%
H
10.5
36.6
|
L
 -41.8%
H
6.8
63.6
|
L
 -83.8%
H
6.8
209.0
|
L
H
6.8
209.0
|
| UroGen Pharma Ltd |
|
1,710.6
|
35.1
|
L
 0.3%
H
34.2
35.6
|
L
 13.8%
H
30.1
35.6
|
L
 21.5%
H
26
35.6
|
L
 99.3%
H
16.5
35.6
|
L
 139.7%
H
12.7
35.6
|
L
 194.5%
H
3.4
35.6
|
L
 113.4%
H
3.4
35.6
|
L
H
3.4
69.6
|
| Vera Therapeutics Inc (Class A) |
|
2,705.5
|
37.7
|
L
 -1.9%
H
37.5
38.5
|
L
 10.1%
H
32.9
38.7
|
L
 10.7%
H
30.6
38.7
|
L
 -7.0%
H
30.6
47
|
L
 80.7%
H
19.1
56.1
|
L
 139.3%
H
9.2
56.1
|
L
 137.9%
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,691.6
|
10.0
|
L
 4.8%
H
9.4
10.2
|
L
 16.5%
H
8.5
10.2
|
L
 9.1%
H
8.2
10.2
|
L
 10.2%
H
8.2
11.7
|
L
 91.8%
H
4.2
11.7
|
L
 -59.7%
H
4.2
25.4
|
L
 -79.0%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
816.6
|
15.1
|
L
 0.9%
H
14.7
15.3
|
L
 7.1%
H
13.8
15.4
|
L
 5.2%
H
12.6
15.6
|
L
 25.2%
H
11.7
19.7
|
L
 6179.2%
H
0.2
50.0
|
L
 218.6%
H
0.1
50.0
|
L
 -25.8%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
366.4
|
4.2
|
L
 -1.9%
H
4.2
4.4
|
L
 4.3%
H
3.9
4.4
|
L
 -1.7%
H
3.6
4.5
|
L
 -24.6%
H
3.6
6.8
|
L
 -15.4%
H
3.6
11.2
|
L
 -54.9%
H
2.1
14.2
|
L
 -91.9%
H
2.1
53.9
|
L
 -73.3%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
25.4
|
0.6
|
L
 -3.1%
H
0.6
0.7
|
L
 8.8%
H
0.5
0.7
|
L
 -4.6%
H
0.5
0.7
|
L
 1.6%
H
0.5
0.7
|
L
 -69%
H
0.4
5.1
|
L
 -64.6%
H
0.4
24.7
|
L
 -99.2%
H
0.4
106.5
|
L
 -99.5%
H
0.4
140.7
|
| Voyager Therapeutics Inc |
|
224.2
|
3.7
|
L
 -0.3%
H
3.7
3.8
|
L
 2.2%
H
3.5
3.8
|
L
 -2.4%
H
3.3
4.0
|
L
 -3.4%
H
3.3
4.5
|
L
 24.9%
H
2.8
5.6
|
L
 -70.1%
H
2.6
12.6
|
L
 -12.3%
H
2.5
14.3
|
L
 -69.7%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
506.4
|
5.3
|
L
 -0.2%
H
5.3
5.4
|
L
 -0.9%
H
5.2
5.5
|
L
 -10.0%
H
5.1
6.7
|
L
 -48.3%
H
5.1
6.9
|
L
 -5.0%
H
5.1
12.3
|
L
 -67.1%
H
3.6
16.5
|
L
 -79.5%
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
1,169.8
|
6.1
|
L
 -1.5%
H
6.1
6.3
|
L
 1.3%
H
5.7
6.3
|
L
 -4.7%
H
5.4
6.6
|
L
 -48.3%
H
5.0
12.7
|
L
 -7.5%
H
5.0
21.7
|
L
 48.7%
H
3.5
21.7
|
L
 -9.9%
H
1.2
21.7
|
L
 -69.6%
H
1.2
56
|
| XBiotech Inc |
|
71.0
|
2.3
|
L
 0.9%
H
2.3
2.4
|
L
 -0.9%
H
2.3
2.4
|
L
 -4.1%
H
2.3
2.5
|
L
 -2.5%
H
2.3
2.7
|
L
 -6.8%
H
2.1
3.6
|
L
 -59.5%
H
2.1
10.0
|
L
 -85.6%
H
2.1
18.5
|
L
 -86.1%
H
2.1
26.4
|
| Exicure Inc |
|
17.8
|
2.8
|
L
 2.2%
H
2.7
2.9
|
L
 0.4%
H
1.7
3.2
|
L
 -0.4%
H
1.7
3.5
|
L
 -37.1%
H
1.7
4.8
|
L
 -62.5%
H
1.7
9.5
|
L
 -54.1%
H
0.3
36
|
L
 -98.8%
H
0.3
297
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,230.9
|
7.1
|
L
 3.3%
H
6.9
7.3
|
L
 3.6%
H
6.8
7.3
|
L
 15.2%
H
5.8
7.3
|
L
 31.1%
H
5.3
7.3
|
L
 58.1%
H
4.4
10.1
|
L
 140.9%
H
1.5
10.1
|
L
 81.4%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
381.1
|
4.0
|
L
 -1.9%
H
4.0
4.2
|
L
 -1.0%
H
4.0
4.4
|
L
H
3.7
4.4
|
L
 -5.6%
H
3.6
4.7
|
L
 51.3%
H
1.4
4.8
|
L
 104.0%
H
0.2
6.6
|
L
 -44.6%
H
0.2
7.4
|
L
H
0.2
172.2
|
| Xencor Inc |
|
1,061.0
|
14.3
|
L
 2.1%
H
13.9
14.5
|
L
 17.2%
H
11.9
14.5
|
L
 26.5%
H
11.1
14.5
|
L
 18.0%
H
10.4
14.5
|
L
 67.6%
H
6.9
18.7
|
L
 -44.2%
H
6.9
27.2
|
L
 -60.8%
H
6.9
43.6
|
L
 2.3%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.6
|
4.7
|
L
 5.4%
H
4.4
4.8
|
L
 -23.0%
H
4.3
6.1
|
L
 688.3%
H
0.3
7.3
|
L
 32.5%
H
0.3
7.3
|
L
 -96.4%
H
0.3
142.5
|
L
 -100.0%
H
0.3
5134428
|
L
 -100.0%
H
0.3
55666440
|
L
 -100.0%
H
0.3
67850460
|
| Zentalis Pharma Inc |
|
263.4
|
3.7
|
L
 0.8%
H
3.6
3.8
|
L
 -2.1%
H
3.5
3.8
|
L
 -8.9%
H
3.4
4.1
|
L
 41.2%
H
2.1
7.0
|
L
 184.6%
H
1.1
7.0
|
L
 -87.2%
H
1.0
29.5
|
L
 -92.9%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
408.0
|
4.3
|
L
 1.7%
H
4.1
4.4
|
L
 16.9%
H
3.5
4.4
|
L
 -1.4%
H
3.3
4.4
|
L
 -21.8%
H
3.3
6.5
|
L
 280.5%
H
1
7.4
|
L
 -64.0%
H
1.0
12.7
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,067.3
|
18.4
|
L
 -0.4%
H
18.1
18.7
|
L
 3.8%
H
17.2
19.1
|
L
 -1.1%
H
16.3
19.1
|
L
 1.7%
H
16.3
25.3
|
L
 -46.7%
H
16.0
41.2
|
L
 -29.2%
H
13.5
44.3
|
L
 -88.5%
H
13.5
178.9
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
9,988.2
|
132.9
|
L
 0.2%
H
132.5
133.0
|
L
 54.1%
H
84.0
133
|
L
 63.7%
H
75.9
133
|
L
 101.2%
H
71.4
133
|
L
 216.6%
H
34.3
133
|
L
H
14.2
133
|
L
H
14.2
133
|
L
H
14.2
133
|
| Intensity Therapeutics Inc |
|
10.8
|
4.0
|
L
 1.0%
H
3.9
4.1
|
L
 1.3%
H
3.6
4.1
|
L
 -15.5%
H
3.5
4.8
|
L
 -33.4%
H
3.5
6.4
|
L
 -42.5%
H
3.5
43.5
|
L
 -96.0%
H
3.5
286
|
L
 -96.0%
H
3.5
286
|
L
 -96.0%
H
3.5
286
|
| Renovaro Biosciences Inc |
|
20.0
|
4.4
|
L
 6.5%
H
3.9
4.8
|
L
 69.4%
H
2.5
5.0
|
L
 95.6%
H
2.0
5.0
|
L
 17.9%
H
1.8
7.6
|
L
 -83.8%
H
1.2
31.0
|
L
H
1.2
420
|
L
H
1.2
420
|
L
H
1.2
420
|
| Elutia Inc (Class A) |
|
46.4
|
1.1
|
L
 5%
H
1.0
1.1
|
L
 8.3%
H
1.0
1.1
|
L
 -9.5%
H
0.9
1.3
|
L
 -4.6%
H
0.9
1.3
|
L
 -42.0%
H
0.5
2.6
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Canton Strategic Holdings Inc |
|
222.7
|
3.2
|
L
 -0.6%
H
3.0
3.3
|
L
 -0.6%
H
3.0
3.8
|
L
 -9.4%
H
2.1
3.8
|
L
 -3.9%
H
2.1
3.9
|
L
 138.1%
H
1.1
9.1
|
L
 -97.7%
H
0.3
163.1
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Gyre Therapeutics Inc |
|
595.8
|
6.1
|
L
 0.2%
H
6.1
6.3
|
L
 4.8%
H
5.7
6.4
|
L
 1.3%
H
5.4
6.7
|
L
 -8.6%
H
5.4
8.2
|
L
 -23.9%
H
5.4
9.4
|
L
 -18.1%
H
5.4
130.5
|
L
 -18.1%
H
5.4
130.5
|
L
 -18.1%
H
5.4
130.5
|
| Lexeo Therapeutics Inc |
|
386.3
|
4.9
|
L
 -2.4%
H
4.9
5.3
|
L
 5.8%
H
4.5
5.3
|
L
 -3.7%
H
4.0
5.3
|
L
 -12.9%
H
4.0
7.0
|
L
 25.8%
H
3.6
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Korro Bio Inc |
|
202.3
|
14.0
|
L
 0.9%
H
13.5
14.5
|
L
 20.3%
H
10.6
14.5
|
L
 20.8%
H
10.3
14.5
|
L
 30.5%
H
9.1
15.6
|
L
 13.6%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Cartesian Therapeutics Inc |
|
306.2
|
10.4
|
L
 4.7%
H
9.8
10.8
|
L
 21.2%
H
8.4
10.8
|
L
 54.4%
H
5.8
10.8
|
L
 60.1%
H
5.6
10.8
|
L
 6.8%
H
5.6
15.6
|
L
 -99.0%
H
5.6
1278
|
L
 -99.7%
H
5.6
4230
|
L
 -99.9%
H
5.6
25199.6
|
| Elevai Labs Inc |
|
6.0
|
1.3
|
L
 -3.0%
H
1.3
1.4
|
L
 -10.3%
H
1.3
1.5
|
L
 -26.4%
H
1.3
2.0
|
L
 -62.8%
H
1.3
14
|
L
 -99.2%
H
1.3
309.1
|
L
H
1.3
499117.9
|
L
H
1.3
499117.9
|
L
H
1.3
499117.9
|
| Spyre Therapeutics Inc |
|
8,290.7
|
95.5
|
L
 -4.8%
H
95.3
102.1
|
L
 14.2%
H
81.7
102.1
|
L
 28.9%
H
68.5
102.1
|
L
 131.4%
H
40.9
102.1
|
L
 536.0%
H
14
102.1
|
L
H
8.8
102.1
|
L
H
8.8
102.1
|
L
H
8.8
102.1
|
| Neurogene Inc |
|
493.5
|
31.2
|
L
 -3.2%
H
31.0
32.6
|
L
 4.6%
H
28.3
33.0
|
L
 12.7%
H
24.9
33.0
|
L
 63.9%
H
18.8
34.0
|
L
 75.8%
H
14.7
37.3
|
L
 120.2%
H
6.9
74.5
|
L
 120.2%
H
6.9
74.5
|
L
 120.2%
H
6.9
74.5
|
| Cg Oncology Inc |
|
5,822.2
|
66.0
|
L
 -0.4%
H
63.8
66.6
|
L
 10.9%
H
59.0
66.6
|
L
 2.7%
H
53.2
66.6
|
L
 1.4%
H
53.2
75.5
|
L
 158.4%
H
23.7
75.5
|
L
H
14.8
75.5
|
L
H
14.8
75.5
|
L
H
14.8
75.5
|
| FibroBiologics Inc |
|
4.3
|
0.8
|
L
 1.2%
H
0.8
0.8
|
L
 -7.9%
H
0.8
0.9
|
L
 -21.9%
H
0.8
1.2
|
L
 -83.9%
H
0.8
5.4
|
L
 -94.1%
H
0.8
15.5
|
L
H
0.8
1100
|
L
H
0.8
1100
|
L
H
0.8
1100
|
| Kyverna Therapeutics Inc |
|
512.5
|
8.4
|
L
 1.6%
H
8.1
8.6
|
L
 3.4%
H
7.8
8.6
|
L
 -2.8%
H
7.4
9.0
|
L
 6.2%
H
7.3
11.6
|
L
 174.6%
H
2.5
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
46.3
|
1.2
|
L
 3.4%
H
1.2
1.3
|
L
 5.1%
H
1.1
1.3
|
L
 -8.9%
H
1.1
1.4
|
L
 -13.4%
H
1.1
1.6
|
L
 -15.2%
H
1.1
4.0
|
L
H
1.1
15
|
L
H
1.1
15
|
L
H
1.1
15
|
| Tevogen Bio Holdings Inc |
|
42.0
|
10.0
|
L
 1.3%
H
9.3
10.0
|
L
 -0.7%
H
9.0
10.3
|
L
 3.5%
H
6.2
12.0
|
L
 90.6%
H
4.1
12.0
|
L
 -83.4%
H
4.1
71
|
L
H
4.1
1054.5
|
L
H
4.1
1054.5
|
L
H
4.1
1054.5
|
| NeOnc Tech Holdings Inc |
|
125.8
|
4.9
|
L
 -5.1%
H
4.8
5.2
|
L
 7.5%
H
4.4
5.7
|
L
 -9.2%
H
4.2
5.7
|
L
 -33.7%
H
3.9
8.1
|
L
 13.9%
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
| LENZ Therapeutics Inc |
|
181.2
|
5.8
|
L
 -0.7%
H
5.7
5.9
|
L
 -12.8%
H
5.7
6.8
|
L
 -23.4%
H
5.7
8.5
|
L
 -44.9%
H
5.7
11.5
|
L
 -80.7%
H
5.7
50.4
|
L
 -76.8%
H
5.7
50.4
|
L
 -76.8%
H
5.7
50.4
|
L
 -76.8%
H
5.7
50.4
|
| Boundless Bio Inc |
|
57.5
|
2.6
|
L
 82.9%
H
2.3
2.8
|
L
 82.9%
H
1.4
2.8
|
L
 77.8%
H
1.4
2.8
|
L
 115.1%
H
1.1
2.8
|
L
 146.2%
H
1.0
2.8
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
443.8
|
11.9
|
L
 2.2%
H
11.4
12.5
|
L
 -6.7%
H
11.4
13.3
|
L
 -14.4%
H
11.2
14.0
|
L
 -2.8%
H
11.2
15.7
|
L
 149.4%
H
3.7
16.3
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
416.1
|
6.4
|
L
 -4.1%
H
6.3
6.8
|
L
 2.4%
H
5.6
6.8
|
L
 -10.3%
H
5.6
7.6
|
L
 -10.3%
H
5.6
8.1
|
L
 47.5%
H
4.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
31.1
|
4.7
|
L
 -4.1%
H
4.6
5.1
|
L
 -4.1%
H
4.6
5.7
|
L
 -3.7%
H
4.5
6.9
|
L
 127.3%
H
1.9
6.9
|
L
 193.1%
H
1.1
6.9
|
L
 -44.1%
H
0.6
9.5
|
L
 -44.1%
H
0.6
9.5
|
L
 -44.1%
H
0.6
9.5
|
| Artiva Biotherapeutics Inc |
|
468.9
|
9.7
|
L
 3.1%
H
9.2
10
|
L
 5.1%
H
8.5
10.5
|
L
 22.6%
H
6.6
10.5
|
L
 81.4%
H
4.7
14.5
|
L
 510.8%
H
1.5
14.5
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
2,221.9
|
46.7
|
L
 6.3%
H
42.0
46.7
|
L
 19.8%
H
37.8
46.7
|
L
 46.6%
H
28
46.7
|
L
 62.8%
H
26.1
46.7
|
L
 379.3%
H
9.5
46.7
|
L
H
4.8
46.7
|
L
H
4.8
46.7
|
L
H
4.8
46.7
|
| BioAge Labs Inc |
|
979.7
|
22.0
|
L
 2.7%
H
20.6
22.5
|
L
 11.1%
H
19.3
22.5
|
L
 32.7%
H
15.1
22.5
|
L
 14.2%
H
14.7
22.5
|
L
 407.8%
H
4.1
24
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| OnKure Therapeutics Inc (Class A) |
|
172.9
|
4.3
|
L
 -3.6%
H
4.3
4.6
|
L
 1.9%
H
4.0
4.6
|
L
 1.7%
H
4.0
4.6
|
L
 2.2%
H
2.9
5.4
|
L
 80.6%
H
1.9
5.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
4.4
|
L
 5.5%
H
4.2
4.5
|
L
 11.9%
H
3.9
5.3
|
L
 -1.8%
H
3.9
5.3
|
L
 -11.4%
H
3.8
5.3
|
L
 216.4%
H
1.3
7.8
|
L
 92.6%
H
1.3
7.8
|
L
 92.6%
H
1.3
7.8
|
L
 92.6%
H
1.3
7.8
|
| Upstream Bio Inc |
|
343.9
|
6.3
|
L
 0.3%
H
6.2
6.5
|
L
 3.6%
H
5.9
6.6
|
L
 -24.5%
H
5.9
8.6
|
L
 -27.1%
H
5.9
10.7
|
L
 -41.9%
H
5.9
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Medicus Pharma Ltd |
|
26.1
|
0.5
|
L
 2.2%
H
0.4
0.5
|
L
 43.8%
H
0.3
0.5
|
L
 53.3%
H
0.3
0.5
|
L
 -9.8%
H
0.3
0.5
|
L
 -81.5%
H
0.3
3.7
|
L
 -93.2%
H
0.3
8.9
|
L
 -93.2%
H
0.3
8.9
|
L
 -93.2%
H
0.3
8.9
|
| Telix Pharma Ltd (ADR) |
|
3,458.9
|
10.2
|
L
 2.1%
H
10.0
10.3
|
L
 7.0%
H
9.5
10.5
|
L
 7.8%
H
8.7
10.5
|
L
 16.7%
H
8.6
11.5
|
L
 -40.5%
H
6.3
17.0
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
1,685.4
|
117.5
|
L
 -1.1%
H
116.8
120.6
|
L
 0.9%
H
109.6
120.9
|
L
 3.1%
H
100
120.9
|
L
 4.5%
H
100
138.6
|
L
 432.9%
H
20.4
151.2
|
L
 764.0%
H
11.2
151.2
|
L
 764.0%
H
11.2
151.2
|
L
 764.0%
H
11.2
151.2
|
| Sionna Therapeutics Inc |
|
1,773.1
|
39.3
|
L
 1.1%
H
37.3
42.3
|
L
 9.1%
H
34.0
42.3
|
L
 -4.5%
H
32.3
44.6
|
L
 7.9%
H
32.3
48.4
|
L
 171.0%
H
13.8
48.4
|
L
H
7.3
48.4
|
L
H
7.3
48.4
|
L
H
7.3
48.4
|
| Zenas Biopharma Inc |
|
1,297.4
|
20.6
|
L
 -1.2%
H
20.4
21.3
|
L
 9.8%
H
17.9
21.3
|
L
 8.3%
H
16.8
21.3
|
L
 -7.9%
H
16.4
23
|
L
 123.6%
H
8.9
44.6
|
L
 96.3%
H
8.9
44.6
|
L
 96.3%
H
8.9
44.6
|
L
 96.3%
H
8.9
44.6
|
| Propanc Biopharma Inc |
|
3.3
|
1.4
|
L
 -2.7%
H
1.4
1.5
|
L
 -33.0%
H
1.4
2.2
|
L
 -18.2%
H
1.3
6.8
|
L
 -51.7%
H
1.3
6.8
|
L
 -98.0%
H
1.3
234
|
L
 -98.0%
H
1.3
234
|
L
 -98.0%
H
1.3
234
|
L
 -98.0%
H
1.3
234
|
| SpyGlass Pharma Inc |
|
658.0
|
19.7
|
L
 1.8%
H
19.1
20.3
|
L
 3.9%
H
17.1
20.3
|
L
 -5.6%
H
17.1
21.6
|
L
 -24.3%
H
17.1
27.2
|
L
 -25.5%
H
17.1
30.6
|
L
 -25.5%
H
17.1
30.6
|
L
 -25.5%
H
17.1
30.6
|
L
 -25.5%
H
17.1
30.6
|
| AgomAb Therapeutics NV ADR |
|
602.8
|
12.2
|
L
 3.4%
H
12.0
12.7
|
L
 22.4%
H
9.8
12.7
|
L
 6.4%
H
8.8
13
|
L
 0.4%
H
8.8
13.8
|
L
 -16.5%
H
8.8
17.5
|
L
 -16.5%
H
8.8
17.5
|
L
 -16.5%
H
8.8
17.5
|
L
 -16.5%
H
8.8
17.5
|
| Generate Biomedicines Inc |
|
1,952.4
|
15.2
|
L
 -4.2%
H
15.0
15.8
|
L
 12.2%
H
13.0
16.2
|
L
 4.8%
H
11.9
16.2
|
L
 24.1%
H
11.1
16.8
|
L
 20.4%
H
11
16.8
|
L
 20.4%
H
11
16.8
|
L
 20.4%
H
11
16.8
|
L
 20.4%
H
11
16.8
|
| Kailera Therapeutics Inc |
|
2,818.1
|
21.8
|
L
 -4.9%
H
21.5
22.6
|
L
 10.6%
H
18.5
22.9
|
L
 2.7%
H
18.5
24.2
|
L
 -16.4%
H
18.5
28.2
|
L
 -16.4%
H
18.5
28.2
|
L
 -16.3%
H
18.5
28.2
|
L
 -16.3%
H
18.5
28.2
|
L
 -16.3%
H
18.5
28.2
|
| Hemab Therapeutics Holdings |
|
1,344.6
|
28.8
|
L
 -9.3%
H
27.8
31.5
|
L
 14.8%
H
23.8
32.0
|
L
 11.2%
H
23.8
32.0
|
L
 -15.3%
H
23
32
|
L
 -15.3%
H
23
32
|
L
 -15.3%
H
23
32
|
L
 -15.3%
H
23
32
|
L
 -15.3%
H
23
32
|
| Odyssey Therapeutics Inc |
|
895.3
|
18.6
|
L
 -0.4%
H
17.6
18.8
|
L
 5.6%
H
17.3
20
|
L
 6.5%
H
16
20
|
L
 13.5%
H
16
20
|
L
 13.5%
H
16
20
|
L
 13.5%
H
16
20
|
L
 13.5%
H
16
20
|
L
 13.5%
H
16
20
|
| Lakefront Biotherapeutics NV |
|
1,911.2
|
29.0
|
L
 0.3%
H
28.7
29.2
|
L
 1.3%
H
28.0
29.2
|
L
 5.6%
H
26.9
29.3
|
L
 1.5%
H
26.4
29.3
|
L
 1.5%
H
26.4
29.3
|
L
 1.5%
H
26.4
29.3
|
L
 1.5%
H
26.4
29.3
|
L
 1.5%
H
26.4
29.3
|
| Conexeu Sciences Inc |
|
289.3
|
10.8
|
L
 -11.3%
H
10.4
12.4
|
L
 10.1%
H
9.6
13.8
|
L
 -24.9%
H
9.6
18.8
|
L
 -17.3%
H
9.6
18.8
|
L
 -17.3%
H
9.6
18.8
|
L
 -17.3%
H
9.6
18.8
|
L
 -17.3%
H
9.6
18.8
|
L
 -17.3%
H
9.6
18.8
|
| Parabilis Medicines Inc |
|
3,383.2
|
27.7
|
L
 0.4%
H
26.2
28.3
|
L
 10.6%
H
24.9
30.2
|
L
 -12.5%
H
24.5
34.5
|
L
 -12.5%
H
24.5
34.5
|
L
 -12.5%
H
24.5
34.5
|
L
 -12.5%
H
24.5
34.5
|
L
 -12.5%
H
24.5
34.5
|
L
 -12.5%
H
24.5
34.5
|